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Urinary tract infections (UTIs) afflict millions of individuals yearly, 
constituting a tremendous global health-care burden. The primary causative 
agents of UTIs are the gram-negative, rod-shaped bacteria, uropathogenic 
Escherichia coli (UPEC). These pathogens are motile and adhesive, with a 
proclivity to colonize diverse niches within the urinary tract; including the kidneys, 
bladder, and ureters. In the bladder, UPEC grow to high levels and often 
associate with the superficial epithelial cells lining the lumen. UPEC can invade 
these superficial epithelial cells to form intracellular reservoir populations, which 
are thought to be a source of recurrent, or relapsing, infections. The susceptibility 
of these intracellular UPEC populations was tested using a panel of commonly 
prescribed antibiotics in a murine model of UTI. Intracellular UPEC were found to 
persist despite treatment with host cell-permeable antibiotics such as 
sparfloxacin and ciprofloxacin that effectively sterilize the urine. In a follow-up 
study, UPEC reservoir populations were more effectively targeted by treating 
infected bladders with chitosan, a chitin-based bladder exfoliant, prior to 
sparfloxacin treatment. Although chitosan administration prior to antibiotic 
treatment significantly decreased UPEC titers, mice still exhibited some relapsing 
UTIs, suggesting that reservoirs still persist either within the bladder or in other 
host tissue. To further elucidate mechanisms of bacterial persistence within the 
urinary tract, several underappreciated bacterial factors were examined that were 
hypothesized to affect UPEC virulence, stress resistance, and persistence. 
	  
iv	  
Bacterial, small, non-coding RNAs (sRNAs) are posttranscriptional 
regulators of gene expression in most prokaryotes and were shown to contribute 
to a wide variety of UPEC stress response and virulence cascades. In a follow-up 
study, the putative UPEC sRNA repertoire was defined using RNA-Seq 
technologies and bioinformatic analyses. Several novel, candidate sRNA 
molecules were identified and characterized, one of which seemingly repressed 
UPEC virulence in the murine UTI model. In a second approach to define 
regulators of UPEC pathogenic behaviors, the tRNA modifying enzyme MiaA was 
identified as a global regulator of UPEC stress response and virulence. MiaA 
adds a prenyl group to A-37, adjacent to the anticodon, in a subset of tRNAs to 
modulate ribosome fidelity and frameshifting. MiaA expression in UPEC was 
responsive to several environmental stresses and deletion or overexpression of 
MiaA interferes with the stress resistance and virulence properties of UPEC. 
Taken together, this thesis defines the robust nature and resilience of 
intracellular UPEC reservoir populations and delineates sRNAs and MiaA as 
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Escherichia coli is a Gram-negative, rod-shaped bacterium commonly 
found in the lower intestine of warm-blooded animals. In the intestine, 
commensal E. coli strains provide the host with essential vitamins and 
advantageous enzymes for digestion of metabolites. However, outside of the 
intestine, some E. coli strains can colonize diverse host niches to cause diseases 
ranging from neonatal meningitis to urinary tract infection (UTI) (31). 
Uropathogenic E. coli (UPEC) are the primary etiologic agent of UTI and rank 
among the most common bacterial infections (11, 12, 16). UTIs thus constitute a 
significant burden on the global health-care system, responsible for over 7.4 
million physicians visits yearly, costing ~1.6 billion dollars in the U.S. alone (11, 
12).  
UTIs can be divided into two major classes: acute uncomplicated UTIs are 
self-limiting infections, whereas chronic infections are highlighted by their 
persistent nature and frequent association with underlying anatomical and/or 
immunological problems. Acute cystitis commonly presents with symptoms such 
as dysuria (burning during urination), frequent urination, urgency, and pyuria 
(cloudy urine). Chronic UTIs display symptoms similar to acute infection, but are 
generally more resistant to antibiotic treatments, persist over longer periods of 
time, and are coincident with higher levels of recurrence. In general, 25-45% of 
women will have an additional UTI within six months of an initial infection (7). 
This high rate of recurrence occurs despite treatment with antibiotics; however, 
increased treatment duration has shown some promise in preventing recurrence 
(22, 30). Additionally, the causative strain for both the index and recurrent 
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infection are often genetically identical, suggestive of a UPEC reservoir 
population present within the urinary tract or elsewhere within the host (25). 
Persistent UPEC reservoirs that are protected from antibiotics and most host 
defenses are proposed to be an important cause of both chronic and recurrent, 
or relapsing, UTIs. 
In order to establish an infection, UPEC ascends into the bladder via the 
urethra and can replicate rapidly within the bladder lumen. A subpopulation of 
UPEC is able to adhere to and invade the large superficial epithelial cells that line 
the bladder lumen and take up residence (Figure 1.1) (10, 19, 20). Invasion of 
these superficial bladder cells occurs via a zipper-like endocytic mechanism, 
resulting in the uptake of UPEC within a membrane-bound vacuole. At this stage 
endocytosed UPEC may be trafficked back out of the epithelial cell into the 
bladder lumen, or enter into a late endosomal, lysosome-like compartment. 
These bacteria can form a long-lived-quiescent intracellular reservoir population 
that remains dormant and therefore less immunogenic. Alternatively, UPEC can 
replicate within the vacuole before breaking out into the cytoplasm, where they 
grow quite rapidly in conjunction with host cytokeratin intermediate filaments to 
form large intracellular bacterial communities (IBCs) (10, 15, 19). IBCs act as a 
dispersal system to propagate the infection throughout the bladder lumen, with 
bacteria replicating to upwards of ~5000 clones per IBC before causing 
disintegration of the host epithelial cell (2, 15). Dispersal from IBCs leads to 
reinoculation of the bladder lumen, seeding bacteria within neighboring and 
underlying epithelial cells. Exfoliation of bladder cells that contain IBCs may also  




Figure. 1.1 UPEC pathogenesis 
UPEC are able to enter the bladder and replicate within the urine. A 
subpopulation of bacteria adheres to, and infrequently invades the host 
epithelium to form intracellular populations of UPEC within endocytic vesicles. 
UPEC may then remain quiescent or begin to replicate within the vacuole, and 
ultimately in the cytosol in conjunction with host factors to form an IBC, which is 
involved in further dissemination of the infection.  
 
 
promote the dispersion of UPEC outside of the host (24). Disruption of the host 
epithelium through IBC formation also facilitates bacterial penetration of the 
underlying intermediate and basal epithelial bladder cells, a process that is 
perpetuated by host immune mechanisms such as exfoliation of the bladder 
epithelium and the influx of neutrophils (10, 19). UPEC invasion of underlying 
tissues provides the bacteria with a stable niche due to the long half-life—roughly 
52 weeks—of the urothelium (14). These entrenched, quiescent bacteria within 
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reseeding the bladder lumen during chronic, recurrent, or relapsing infection. 
Once the reservoir population is established, subsequent rounds of infection 
occur as individual IBCs form, burst, and reinoculate the urinary tract.  
Establishment and maintenance of a persistent infection is achieved 
through the coordinated efforts of innumerable virulence factors and other 
systems, including those that affect bacterial motility, adhesion to and invasion of 
epithelial cells, environmental sensing, immune evasion, and stress responses. 
UPEC have a variety of virulence factors, including multiple iron scavenging 
systems, adhesive organelles, and toxins such as α-hemolysin and cytotoxic 
necrotizing factor to disrupt host membranes, release nutrients, and manipulate 
host-signaling cascades (9, 29). UPEC also possess distinct polysaccharide 
capsules and sugar moieties on their outer membrane to reduce immunogenicity 
and limit exposure to environmental assaults. Relative to non-pathogenic 
isolates, pathogenic strains commonly exhibit increased resistance to nutrient 
limitation and environmental stressors (29). As an example, bacterial pathogens 
may acquire multiple catalase genes to enhance resistance to oxidative stress or 
may encode numerous iron scavenging systems to obtain necessary iron from 
the environment or host (28).  
In addition to virulence factors, all bacteria must have mechanisms for 
obtaining energy from the environment. An elegant study by Alteri et. al. recently 
identified several metabolic systems—protein import, gluconeogenesis, and the 
tricarboxylic acid cycle—as indispensible for UPEC virulence in the urinary tract 
(1). Glycolysis, the pentose-phosphate pathway, and the Entner-Doudoroff 
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pathway, all of which provide the cell with energy through the generation of 
pyruvate, were dispensable for virulence during UTI in this study (1). The 
superfluous nature of these metabolic systems in the urinary tract is in contrast to 
their requirement in the intestinal tract, suggesting that the ability to utilize 
alternate energy sources and metabolic pathways significantly impacts the 
fitness of UPEC during a UTI. Metabolic intermediates also play a direct role in 
bacteria-to-bacteria signaling through processes like quorum sensing, where 
concentrations of metabolic breakdown products signal the bacterial population 
to undergo a specific behavior, such as biofilm formation (17). Similar to the 
mechanisms of quorum sensing, UPEC recognize host-produced metabolic 
compounds using them as a sort of molecular roadmap. Recognition of the 
amino acid D-serine, which is produced in abundance in the host urinary tract, 
signals UPEC to up-regulate pathways that optimize its growth, motility, and 
virulence within the bladder lumen (3, 23). Combined, these observations 
indicate complex interplay between bacterial metabolic processes, virulence, and 
niche recognition during the course of a UTI.  
In bacteria, a multitude of regulatory mechanisms are in place to control 
the expression of virulence factors, metabolic enzymes, and stress response 
proteins. These mechanisms range from altering promoter binding efficiency and 
transcription factor abundance to regulation by posttranslational modifications. 
One of the most common forms of bacterial regulation is the two-component 
system, where a membrane-bound histidine kinase senses environmental stimuli 
and transfers a signal to a response regulator, which in turn alters gene 
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expression. Posttranscriptional control of gene expression by small, non-coding 
RNAs (sRNAs) comprises another important regulatory mechanism. sRNAs, 
ranging in size from 50-500 nucleotides (nt), base-pair with cognate, target 
mRNA sequences, often in the presence of the RNA chaperone Hfq, and thereby 
influence mRNA translation and stability. sRNA molecules regulate diverse 
cellular activities, from outer membrane porin expression and basal metabolic 
function to stress response and virulence (4, 5, 8, 18). Most sRNA molecules 
appear to function primarily in fine-tuning gene expression (26).  
Contrasting with gene specific regulation by sRNA molecules are more 
global regulatory mechanisms such as translational control through tRNA 
modification. tRNAs can be modified with upwards of 100 different modifications, 
ranging from methylation marks to isoprenyl groups (21). Each of these 
modifications affects the process of translation differently, but most appear to 
affect translational rates and fidelity. Several tRNA modifying enzymes regulate 
large subsets of tRNA molecules and can have a substantial impact on protein 
expression (6, 13, 27). These modifying enzymes, such as MiaA and Tgt, are 
postulated to serve as global regulators of stress response (6, 13, 27). 
Regulation of these enzymes is hypothesized to enable rapid, broad-scale 
changes in response to environmental stresses directly altering protein 
abundance and, perhaps, functionality. Combined, sRNAs and tRNA modifying 
enzymes may provide bacteria with the ability to fine-tune gene expression to 
more precisely respond to environmental stimuli, optimizing metabolic activities, 
stress response pathways, and virulence.  
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Thesis Research Summary 
The thesis research compiled here aims to define molecular aspects of the 
UPEC reservoir population during infection of the urinary tract through the use of 
in vitro assays and a murine model of infection. Chapters 2 and 3 will relate 
research towards understanding the confounding issues of UTI recurrence, 
namely the inability to clear the UPEC reservoir population from the bladder. 
Chapters 4 and 5 will transition to the identification and characterization of sRNA 
regulatory networks in UPEC, highlighting contributions of specific sRNA 
molecules to stress response and persistence. Chapter 6 will then describe the 
interplay between translational regulation by the tRNA modifying enzyme MiaA, 
metabolic flexibility, and stress response during a UTI. Chapters 4 through 6 
begin to elucidate the molecular mechanisms that enable UPEC to persist within 
the urinary tract, despite attacks from the host immune system and other harsh 
environmental stressors. Chapter 7 will synthesize the content of this thesis and 
provide extrapolations on what is to come in the field of UPEC pathogenesis. 
Finally, several appendices will delineate bacterial communication through direct 
interactions with their neighbors, as well as mechanisms used by the host to 
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Abstract 
Chitosan, a water-soluble, chitin-based derivative, selectively triggers 
exfoliation of superficial bladder epithelial cells. Chitosan-induced exfoliation of 
superficial cells was used as a tool to show that UPEC were able to invade and 
form reservoir populations in underlying intermediate and basal epithelial cells. 
Chitosan treatment of in vitro growing bacteria resulted in overly adhesive 
bacteria, which more efficiently formed biofilms and exhibited increased 
association to cultured 5637 bladder epithelial cells. Scanning electron 
micrographs of infected mouse bladders revealed high levels of often-filamentous 
bacteria on the bladder surface at 3 and 7 days after chitosan treatment, 
suggestive of increased resurgence and exit from their intracellular niche. 
Treatment of infected mouse bladders with chitosan and cell-permeable 
antibiotics, such as sparfloxacin and ciprofloxacin, resulted in enhanced removal 
of UPEC reservoir populations in the murine urinary tract. Despite near-complete 
clearance of UPEC from the bladder after treatment, these mice still displayed 
recurrent infections as determined by daily urine analysis over the course of two 
weeks following cessation of antibiotic treatment. It remains possible that nearby 
tissues, such as the ureters or vaginal mucosa, may harbor UPEC populations 
capable of re-colonizing the bladder following antibiotic treatment. Overall, 
chitosan treatment followed by ≥7 days of antibiotics offers a unique treatment 
regiment for removal of embedded reservoir populations in the bladder 
epithelium by forcing UPEC resurgence. Further research will refine the efficacy 
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of this treatment as a therapy for use in human patients with recurrent, or 
relapsing, urinary tract infections.  
 
Introduction 
The mammalian bladder mucosa, being comprised of a transitional 
epithelium (urothelium) and an underlying lamina propria, functions as a strong 
permeability barrier that keeps urine and other elements within the bladder lumen 
from entering surrounding tissues. The highly vascularized lamina propria 
merges with the submucosa, which in turn sits atop a layer of smooth muscle that 
is surrounded in part by a serosal covering and an adventitia made up of 
connective tissue.  The urothelium itself is composed of layers of immature 
intermediate and basal bladder epithelial cells (BECs) underlying a single layer of 
much larger, terminally differentiated binucleate superficial cells that face the 
bladder lumen (13, 19, 22). Intermediate, and possibly basal BECs, move 
towards the apical surface and differentiate to fill vacancies created as superficial 
cells are shed (32). Normally, the urothelium has an especially slow turnover rate 
of 6-12 months, but upon injury and exfoliation of the superficial cells, the 
underlying immature cells are rapidly mobilized and differentiated (10). As they 
differentiate into superficial cells, intermediate cells undergo multiple changes, 
including marked increases in size, fusion with neighboring intermediate cells, 
and finally the redistribution of actin filaments to sites along basolateral surfaces 
(2, 19, 22, 32). The ability of urothelium to quickly regenerate itself when 
damaged is impressive, and likely reflects the importance of this mucosal barrier 
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in guarding against the uptake of unwanted metabolites and infiltrating microbial 
pathogens (10, 26).   
The sterility of the urinary tract is routinely challenged by a diversity of 
bacterial pathogens, which if not eliminated can result in the establishment of a 
urinary tract infection (UTI). Most UTIs are caused by strains of uropathogenic 
Escherichia coli (UPEC) (35). UPEC strains, which are often motile and encode 
numerous adhesive organelles and other virulence factors (35), likely originate in 
the colon, but can be introduced into the urinary tract via contamination of the 
urethra meatus and urethra, facilitated by poor hygiene, sexual intercourse, or 
anatomical defects (9). UTIs are often acute in nature, being associated with the 
transient detection of bacteria in urine and accompanying symptoms that can 
include pelvic pain, pyuria, dysuria, and the frequent, urgent need to urinate (8). 
Although often self-limiting or treatable with short-course antibiotics, UTIs are 
prone to recur in many individuals and can develop into chronic, long-term 
infections that can last from a few weeks to years. Occasionally, UPEC 
colonization of the bladder can also serve as a staging ground for the further 
spread of the pathogens into the kidneys and/or bloodstream.  
The capacity of many UPEC isolates to persist within the bladder and 
cause recurrent and chronic UTIs is facilitated by the ability of UPEC to bind and 
invade the urothelium (6, 23, 30, 34). UPEC utilize adhesive fibers known as type 
1 pili to both attach to and invade BECs (6, 37). Internalized bacteria can be 
quickly shuttled back out of the host cells or trafficked into actin-bound, 
lysosome-like compartments where they can persist in a seemingly quiescent 
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state, sequestered away from the flow of urine and host immunosurveillance 
mechanisms (7, 23, 24). These quiescent bacteria are thought to serve as 
reservoirs for recurrent (or more accurately, relapsing) and chronic UTIs (7). 
Within terminally differentiated superficial BECs, UPEC can break into the host 
cytosol and rapidly grow in close association with cytokeratin intermediate 
filaments, forming large biofilm-like aggregates referred to as intracellular 
bacterial communities (IBCs) (1, 14, 24). Triggers that stimulate the development 
of IBCs, versus the establishment of quiescent intracellular reservoirs, are not 
entirely clear, but appear to be affected by the differentiation status of the host 
cell and the distribution of actin filaments (7). IBCs are not especially long-lived 
structures and are susceptible to disruption by antibiotics (3). The build-up and 
eventual dispersal (or shedding) of IBCs likely facilitates the spread of UPEC 
both within the urinary tract and to other hosts, promoting further rounds of acute 
and recurrent/relapsing infections (1, 24).  
Acute UTIs are commonly treated with short-course antibiotic regimens 
such as Bactrim (sulfamethoxazole/trimethoprim), nitrofurantoin, amoxicillin, or 
select fluoroquinolones, with relatively high success rates (12). Chronic UTIs 
respond poorly to short-course antibiotic treatments, which often fail to 
completely eliminate UPEC reservoir populations (3, 24, 29). Long-term antibiotic 
treatments show more promise, but come with a greater risk of side effects and 
development of antibiotic resistance, driving interest in alternative treatment 
options. A plethora of vaccine targets have so far yielded little clinical success in 
eradicating UPEC from the bladder. For example, vaccination attempts using 
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Solco-Urovac, a mix of 10 heat-inactivated uropathogenic strains was initially 
promising, but proved to be too allergenic for consistent, widespread usage (28). 
Other attempts at vaccine development have targeted conserved pathogenic 
elements such as capsule, LPS core antigen components, pili, and toxins such 
as α-hemolysin with limited success. Despite many years of intensive research 
and development, these vaccines provide only short-term protective immunity, 
suggesting a limited role of the adaptive immune system in fighting UTIs. Recent 
strategies aimed at targeting panels of pathogen-associated molecules are laying 
the groundwork for development of more efficacious vaccines, but the broad 
application and optimization of this approach remains distant (33). Novel 
therapeutic regimens will likely be needed to support current vaccinology efforts.  
Recently, using a mouse UTI model, we demonstrated that many 
antibiotics effectively sterilize the urine, while leaving intracellular UPEC 
reservoirs buried within the urothelium mostly untouched (3). The nonreplicating 
status of these bacteria, coupled with the barrier function of the urothelium, likely 
contributes to the recalcitrant nature of UPEC reservoirs. In this study, we 
explored the use of the linear polysaccharide chitosan as a tool to expose and 
better target UPEC reservoirs within the urothelium. Chitosan is a deacetylated 
form of chitin derived from shellfish. It is reported to have bactericidal activity, is 
naturally biodegradable by lysozyme, and is approved for use in human patients 
as a drug carrier molecule (21, 36). Chitosan is able to disrupt epithelial cell tight 
junctions, and its instillation into the bladder causes rapid exfoliation of the 
superficial cell layer of the urothelium without eliciting any overt signs of 
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inflammation (16, 32). Following chitosan administration via catheterization, the 
urothelium barrier function is restored within 7 days ((32) and personal 
communication P. Veranic). Here we show that chitosan can be used to remove 
the superficial cell layer in murine bladders, thereby stimulating the resurgence of 
UPEC from intracellular reservoirs within the immature layers of the urothelium. 
Chitosan had minimal effect on the growth of a UPEC reference isolate in broth 
culture, but did promote biofilm formation and the development of unusual 
tubules that linked individual bacteria. When used in association with antibiotics, 
chitosan allowed for more complete removal of the reservoir populations within 
the bladder, suggesting that chitosan may be valuable for the treatment of 
chronic and recurrent UTIs.  
 
Results 
Chitosan affects UPEC growth and biofilm formation 
In previous reports, chitosan has been shown to inhibit the growth of some 
bacterial strains (21). To assess the effect of chitosan on UPEC, the reference 
UPEC cystitis isolate UTI89 was grown shaking at 37°C in modified M9 minimal 
media supplemented with 0.02, 0.002, or 0.0002% chitosan or with buffer 
(phosphate buffer, pH 4.5) alone. Growth of UTI89 in the presence of 0.02% 
chitosan was delayed by over 1 h, but was otherwise unimpeded (Fig 3.1A and 
data not shown). In microtiter plate-based assays with static cultures, chitosan 
greatly enhanced biofilm formation by UTI89 in a dose-dependent fashion (Fig 
3.1B). Growth of bacteria on glass coverslips in the presence of 0.002% chitosan  
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Figure 3.1 Chitosan affects in vitro growth of UPEC  
(A) Growth of UTI89 in the presence of increasing concentrations of chitosan 
(0.0002, 0.002, 0.02%) or equal volumes of pH 4.5 phosphate buffer. Graph is 
from representative data collected from one of three experiments done in 
triplicate. Error bars were negligible and not shown for clarity. (B) In vitro biofilm 
formation of UTI89 incubated with increasing concentrations of chitosan or buffer 
as described above. Data was combined as three separate experiments 
performed in quadruplicate. Error bars indicate standard error of the mean with P 
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caused UTI89 to form large aggregates that were not apparent with lower 
concentrations of chitosan or with buffer alone (Fig. 3.2A-D). These chitosan-
induced biofilm-like aggregates were associated with large amounts of undefined 
extracellular material (Fig. 3.2D), and also contained many filamentous bacterial 
cells as are often observed with bacteria under stress (Fig. 3.2C).  
 
Chitosan increases UPEC cellular association 
The effects of chitosan on interactions between UTI89 and host cells were 
assessed using the bladder epithelial cell line designated 5637. Chitosan (0.0002 
and 0.002%) had no effect on the attachment or viability of 5637 cells, but did 
have a slight, though significant, inhibitory effect on growth of UTI89 in the cell 
culture medium (RPMI, Fig. 3.3A). Interactions between UTI89 and the BECs 
were drastically increased following a 2-h infection in the presence of chitosan 
treatment (Fig. 3.3B). In contrast, 0.002% chitosan decreased bacterial entry into 
the host cells (Fig. 3.3C), while having no significant effect on intracellular 
survival of the pathogen over a 24-h period (Fig. 3.3D).  
 
Use of chitosan indicates that UPEC reservoirs reside within 
all layers of the urothelium 
Previous work indicated that instillation of chitosan into the bladder lumen for 20 
min will induce robust exfoliation of the superficial cells, leaving the underlying 
urothelium mostly intact (32). Using adult female CBA/J mice, we confirmed 
these findings, showing that chitosan promotes the rapid detachment of nearly all  




Figure 3.2 Chitosan treatment results in increased biofilm formation and 
filamentous UPEC 
 
(A-D) Immunofluorescence images of UTI89 incubated with increasing 
concentrations of chitosan or buffer and stained with anti-E. coli antibody. Panel 
C specifically shows an example of a filamentous bacterium present after 
treatment with 0.02% chitosan. Experiments were repeated at least twice in 
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Figure 3.3 Chitosan treatment decreases BEC invasion despite increased 
association  
 
(A) Chitosan treatment (0.002 or 0.02%) results in decreased growth in RPMI 
tissue culture media in the presence of 5637 bladder epithelial cells. (B) Chitosan 
treatments result in increased association of UTI89 with BECs in culture. (C) 
Invasion of UTI89 into BECs was measured by gentamicin-protection assays, 
where the cell-impermeable antibiotic gentamicin kills extracellular bacteria. Data 
was graphed as an index that normalizes invasion to bacteria associated with 
epithelial cells. (D) Intracellular replication of UTI89 was measured in the 
presence of chitosan or buffer after an overnight incubation in low concentrations 
of gentamicin. All cell culture experiments were performed at least three times in 
triplicate and combined. Error bars indicate standard error of the mean with P = 
*<0.05, **<0.01, ***<0.001. 
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of the large, binucleate superficial BECs, exposing the smaller mononucleate 
immature cells of the urothelium (Fig. 3.4A – B). Previous microscopy-based 
studies indicate that UPEC can invade all layers of the bladder urothelium (3, 7, 
23, 24). Taking advantage of the ability of chitosan to strip away the topmost 
layer of superficial cells, we set out to quantify the ability of UPEC to invade 
mature versus immature BECs in vivo. Mice were treated with chitosan or 
phosphate buffer alone for 20 min followed by washes with phosphate buffered 
saline (PBS). Mice were then allowed to recover for 4 h prior to inoculation of 
UTI89 via transurethral catheterization. After 1 h, bladders were recovered, 
quartered, and incubated for an additional hour in the presence of gentamicin (10 
µg/ml) in order to kill any extracellular bacteria. After additional washes to 
remove the antibiotic, bladders were homogenized and the numbers of surviving 
bacteria enumerated by dilution plating. Results shown in Fig. 3.4C indicate that 
UPEC has the capacity to invade both the superficial and immature cells of the 
bladder similarly. 
We next asked if UPEC could penetrate and persist equally well within 
both mature and immature BECs. Untreated mice were inoculated with UTI89 via 
catheterization and the infection was allowed to proceed for 3 d. At this time 
point, IBCs are rare and intracellular reservoir populations have been established 
(1, 14). Infected mice were then treated with phosphate buffer alone or with 
chitosan to remove the outermost cell layer. After several washes with PBS,  
bladders were collected and bacteria present were quantified. In these assays, 
chitosan treatment decreased bacterial titers in the bladder slightly, but this 
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change was not statistically significant (Fig. 3.4D). These results confirm that 
UPEC can establish itself within all layers of the urothelium. 
 
Resurgence of UPEC after chitosan treatment 
The exfoliation of infected superficial BECs occurs normally during UTI, 
driving the differentiation of underlying cells that may contain UPEC reservoirs 
(25, 31). It has been proposed that the differentiation process, with 
accompanying changes in the actin cytoskeleton, can stimulate the resurgence of 
UPEC (7). To investigate this possibility, bladders of CBA/J mice were treated 
with chitosan 3 d after infection with UTI89, washed, and then collected and 
imaged by scanning electron microscopy (SEM) at 1, 3, and 7 d postchitosan 
treatment. At days 1 and 3, large numbers of bacteria were visible on the apical 
surface of some bladders (Fig. 3.5). Similar levels of bacteria were observed less 
often at day 7 and in untreated, infected bladders, and not at all in uninfected 
controls. These observations suggest that chitosan treatment and subsequent 
regeneration of the urothelium can spur the resurgent growth of UPEC from 
established reservoirs. Many of the bacteria present on the bladder surface 
following chitosan treatment were filamentous, in line with previous work showing 
that filamentation is not uncommon among UPEC growing within the stressful 
confines of BECs and the bladder lumen (11, 15). Residual levels of chitosan, as 
well as the presence of oxidative radicals that can activate the SOS response, 
may both contribute to development of the filamentous bacteria (see Fig. 3.2E 
and (11, 15, 20)).  Of note, many of the bacteria observed in this analysis were 
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Figure 3.4 UPEC invades basal and intermediate bladder epithelial cells  
 
7-8 wk old CBA/J mice from Jackson Laboratory were treated with (A) buffer 
control or  (B) 50 µl of 0.02% chitosan for 20 minutes as described in the 
methods. Mice were sacrificed, bladders aseptically removed, splayed, and 
nuclei were stained with Hoeschst dye. The ability of UTI89 to invade 
intermediate and basal epithelial cells was tested by treating mice with control 
buffer or 50 µl of 0.02% chitosan for 20 minutes. 4 h after chitosan treatment, 
mice were infected with 107 UTI89 and allowed to incubate for 1 h. At this time 
mice were sacrificed and bladders were removed, homogenized, serially diluted, 
and titered for the presence of bacteria. (D) Mice were infected as described 
above and allowed to develop reservoir populations. At 3 d post infection, mice 
were treated with chitosan or buffer as previously described, washed with 
profusely with PBS, and immediately sacrificed. Bladders were removed, 
homogenized, and titered as described above. Graphs show median value with P 




















































Figure 3.5 Chitosan treatment causes resurgence of UPEC reservoir into 
the bladder lumen 
 
(A) SEM images of uninfected, unmanipulated bladder as a control. SEM images 
of (B-C) 1 d, (D-E) 3 d, and (F) 7 d time points after chitosan treatment of a 3 d 
infected mouse bladder. Magnifications are shown at the bottom of the images.  
Uninfected Infected 1 d post Chitosan
Infected 3 d post ChitosanInfected 3 d post Chitosan 
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interconnected by tubular projections (Fig. 3.5). The nature of these projections 
remains unknown, but they appear too large to be pili and too numerous to be 
flagella as typical of this particular UPEC isolate.  
 
Chitosan enhances the efficacy of antibiotics within the bladder 
UPEC present in the bladder at 3 d postinoculation are, for the most part, 
localized within the urothelium barrier and are consequently protected from the 
effects of both host cell-impermeable and -permeable antibiotics (3). By forcing 
the resurgence of UPEC from reservoir populations, we reasoned that chitosan 
may render the bacteria more susceptible to host defenses and antibiotics. To 
assess this possibility, mice were treated with chitosan or phosphate buffer alone 
at 3 d postinoculation with UTI89. Mice were subsequently administered 3 or 7 
daily doses of antibiotics, including the host cell-impermeable aminoglycoside 
gentamicin and two host cell-permeable fluoroquinolones, ciprofloxacin and 
sparfloxacin. Controls were given with water (carrier) alone by gavage. The 
animals were then allowed 3 additional days to clear the antibiotics from their 
systems before bladders were recovered, homogenized, and plated to determine 
bacterial titers.  
In these assays, chitosan treatment without subsequent administration of 
antibiotics stimulated marked, though sporadic, outgrowth of UTI89 in the 
bladders of some, but not all of the test animals (Fig. 3.6), corroborating with 
results from the SEM analysis. The delivery of antibiotics for either 3 or 7 d had 
minimal effects on bacterial titers within the bladder tissue, in line with previous 




Figure 3.6 Chitosan treatment coupled with antibiotic treatment reduces 
bacterial titers  
 
Mice, infected with 107 UTI89, were treated on day 3 with buffer or chitosan (50 
µl of 0.02% chitosan). Buffer/chitosan treatment was followed by either a 3 d or 7 
d control or antibiotic treatment (Gent = gentamicin, SPX = sparfloxacin, CIP = 
ciprofloxacin). A schematic showing the administration of chitosan and antibiotics 
is diagrammed below the graph. Graph is combined data from two separate 












Antibiotic Duration (d)   
-     +    +    -     +    -     +     -     +






Experiment Length (d) 9 13










	  	   	  
39	  
observations (3). However, the treatment of bladders with chitosan prior to 
antibiotic administration significantly reduced bacterial titers, an effect that was 
much more pronounced with the 7 d antibiotic treatments (Fig. 3.6). These data 
indicate that chitosan can be used to enhance the efficacy of antibiotics within 
the bladder, likely by stimulating the efflux of UPEC reservoirs as well as 
decreasing the permeability barrier function of the urothelium.   
 
Mice show recurrence despite near elimination of UPEC 
bladder reservoirs 
By greatly reducing the level of detectable UPEC reservoirs within the 
bladder tissue, we hypothesized that chitosan treatment followed by the 
administration of sparfloxacin would result in decreased episodes of overt UTI 
recurrence as measured by urine titers. To test this, infected mice were treated 
on day 3 with chitosan or buffer, and then given sparfloxacin or water control for 
7 consecutive days. Urine titers were collected once daily for >80% of the mice 
and plated directly on LB agar plates, noting the volume of urine collected. 
Samples that produced bacterial lawns when plated were assumed to contain a 
minimum of 4000 CFU. Urine titer data for 15 d following cessation of antibiotic 
treatment is shown in Fig. 3.7A. Titers of >104 colony forming units (CFU)/ml 
were counted as a recurrent/relapsing UTI. These were detected in all 
experimental groups over the course of these assays, though untreated mice 
receiving neither chitosan nor sparfloxacin had significantly more individual   
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Figure 3.7 Chitosan and antibiotic treatment fails to prevent recurrence 
 
(A) Urine titers measuring recurrence in infected mice mock treated or treated 
with 7 days of sparfloxacin, or sparfloxacin following chitosan treatment on day 3. 
Urine counts were not serially diluted, and thus a lawn, or a count over 1000 
CFU/ml was considered as a recurrence event (above dotted line). (B) Total 
recurrence events observed for each mouse from panel A over the 15 d 
measurement. Each individual collection from each individual mouse was 
described as recurrent or below limit of recurrence. Statistics were performed as 
(A) Fischer’s Exact Test, or (B) Mann Whitney U test with P = *<0.05, ***<0.001. 
Graphs are combined data from two separate experiments with greater than 11 
mice per group. 
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recurrence events as determined by urine titers over the course of 15 d (Fig. 
3.7B and data not shown). All 11 untreated mice exhibited a recurrence at some 
point during the 15 d period, whereas nearly half  (5) of the mice treated with 
chitosan and sparfloxacin had no recurrence events (Fig. 3.7B). Mice treated with 
sparfloxacin alone faired only slightly worse. Both test treatments significantly 
delayed the onset of recurrent UTIs, with urine titers rising only after 3 or 7 days 
following the sparfloxacin or chitosan plus sparfloxacin treatments, respectively.   
 
Discussion 
In this manuscript, chitosan was used as a tool to trigger selective 
exfoliation of superficial bladder epithelial cells in a murine model of UTI. 
Chitosan acts to disrupt tight junctions between superficial bladder cells resulting 
in exfoliation of host epithelial cells, with little observable inflammation (32). 
Interestingly, chitosan only acts on the surface layer of the urothelium, leaving 
the intermediate and basal layers of epithelial cells mostly intact (32). Using 
chitosan, the UPEC reservoir populations were observed to be present in both 
the underlying layers of the urothelium and the superficial bladder epithelial cells. 
Additionally, UPEC was shown to invade underlying epithelial cells as efficiently 
as superficial cells during murine infection.  
Massive efflux of UPEC into the bladder lumen was observed after 
chitosan treatment of mice, suggesting chitosan can force the resurgence of 
UPEC from the intracellular reservoirs, perhaps by triggering the differentiation of 
the immature host cells or otherwise altering the intracellular milieu so that 
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bacterial growth and release is favored. SEM imaging of infected bladders after 
chitosan treatment revealed numerous bacteria on lumenal surface, many of 
which were filamentous. These bacteria often elaborated unusual interbacterial 
connections that are morphologically reminiscent of recently described 
“nanotubes.” Bacterial nanotubes have been shown to mediate the direct transfer 
of proteins and, possibly, RNA between bacterial cells (5). These tubules also 
provide a network for exchange of molecules both within and between species 
and likely contribute structurally to bacterial communities. It is not yet clear if 
chitosan promotes the formation of these structures, although their presence at 
late time points following the administration of chitosan and in untreated bladders 
suggests that this is not the case.  
Treatment of infected mouse bladders with chitosan followed by three or 
seven daily doses of antibiotics resulted in significant decreases in bacterial titers 
within the bladder tissue. In these assays, the 7 d treatments with either 
sparfloxacin or ciprofloxacin were notably more effective and may have 
substantial therapeutic potential. However, several pitfalls do exist with the 
proposed strategy. Chitosan can stimulate biofilm formation and increases 
interactions between UTI89 and BECs in vitro, which and could thereby promote 
bladder colonization under some conditions. Of even greater concern, the 
selective exfoliation of the superficial cell layer impairs barrier function of the 
urothelium and could consequently allow for broader dissemination of UPEC or 
enable infection by opportunistic pathogens. However, the combined use of 
antibiotics with chitosan ameliorates these concerns.  
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A model for UPEC colonization and resurgence from within the immature 
cells of the urothelium is presented in Fig. 3.8 UPEC may gain entry to the 
underlying immature cells of the bladder as the integrity of the urothelium barrier 
is compromised due to the exfoliation of infected superficial cells and the influx of 
neutrophils. Within the basal and intermediate cells of the urothelium, UPEC do 
not multiply and instead establishes long-lived quiescent intracellular reservoirs. 
These reservoirs may eventually be delivered back to the lumenal surface of the 
bladder as their immature host cells migrate and differentiate into superficial 
epithelial cells. Changes in the intracellular environment, including perhaps the 
redistribution of actin filaments, may enable UPEC to reinitiate growth, leading 
the bacteria to exit the host vacuolar compartment and multiply within the host 
cytosol in close association with cytokeratin intermediate filaments (7, 17). 
Replication and subsequent efflux into the bladder lumen promotes the further 
dispersal of UPEC, which in turn can stimulate host inflammatory responses and 
the full spectrum of symptoms associated with a recurrent UTI. By driving the 
resurgence of UPEC reservoirs in the presence of antibiotics, chitosan may be 
able to interrupt this cycle of infection that likely contributes to the widespread 
nature of recurrent UTIs. The fact that chitosan treatment in combination with 
antibiotics could not prevent recurrent/relapsing infection in all of the animals 
tested in our assays indicates that the use of chitosan can be further optimized to 
better eradicate UPEC reservoirs within the bladder that may be present at levels 
below our limit of detection. It is also possible that the presence of bacterial 
reservoirs within nearby tissues, such as the ureters or the vaginal mucosa, may 






Figure 3.8 Model of UPEC action  
 
(A) UPEC invade the transitional epithelium taking up residence in both 
superficial epithelial cells and underlying epithelial cells. (B) UPEC resident in 
underlying cells vertically move through the hierarchy of differentiating cells as a 
quiescent reservoir as the host cell progresses towards a terminally differentiated 
superficial epithelial bladder cell. (C) UPEC replicates and exits the quiescent 
intracellular reservoir within the host endocytic compartment (vacuole) before 
replicating rapidly in the cytosol to form IBCs. IBCs then act to disseminate 
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harbor UPEC reservoirs that can recolonize the bladder following the cessation 
of antibiotic treatment. Recolonization of the bladder in these assays is not likely 
attributable to fecal contamination of the urinary tract, as we have found that 
mice carrying UPEC within their intestines do not spontaneously acquire UTIs 
(unpublished observations). Formation of IBCs allows for dispersal of the 
bacteria and ultimately reinoculation of the bladder lumen, and to a low 
frequency, further invasion of host epithelial cells. In summary, UPEC slowly 
move towards the surface epithelium in differentiating epithelial cells, before 
undergoing resurgence to further disseminate the infection and persist within the 
urinary tract. 
 The idea of inducing bladder cell exfoliation as a therapeutic option for the 
treatment of chronic and recurrent UTIs is not new, and has been explored 
experimentally in previous work using protamine sulfate. When instilled into the 
bladder lumen, protamine sulfate triggers massive loss of the superficial cells as 
well as other BECs, often stripping away the urothelium to the basement 
membrane (25, 27). Chitosan offers a more restrained alternative, since it acts 
primarily on only the uppermost layers of cells. It also acts rapidly, induces little, if 
any, inflammation, and is likely less prone to elicit painful responses as does 
protamine sulfate (32). Finally, there are already anecdotal reports from outside 
of the USA of the use of chitosan to successfully treat human patients with 
chronic UTI (P. Veranic, unpublished), supporting our conclusion that chitosan 
may have tangible therapeutic value when used synergistically with antibiotics.  
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Materials and Methods 
Reagents 
Chitosan hydrochloride, low molecular weight, (FMC Corporation) was 
prepared as a 0.02% stock (w/v) in phosphate buffer (1.6 g NaCl, 0.095 KH2PO4, 
0.472 NaHPO4 x 12 H2O Q.S. to 1 L H2O; pH 4.5). All antibiotics and chemicals 
were purchased from Sigma-Aldrich and used at the concentrations listed in the 
text.  
 
Bacterial strains and growth 
The prototypic UPEC cystitis isolate UTI89 has been described previously 
(4, 24). Bacteria were grown from frozen stocks in either Luria-Bertani (LB) broth 
or modified M9 minimal medium (6 g/liter Na2HPO4, 3 g/liter KH2PO4, 1 g/liter 
NH4Cl, 0.5 g/liter NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 0.0025% 
nicotinic acid, 0.2% casein amino acids, and 16.5 µg/ml thiamine in H2O) at 
37°C. Growth curve analysis was performed as previously described using a 
Bioscreen C machine (Growth Curves USA) with optical density measured at 600 
nm every 30 m (18). 
 
Biofilm assays 
In vitro microtiter plate-based biofilm assays were performed as previously 
described. Briefly, UTI89 was diluted 1:100 from overnight shaking cultures into 
M9 medium. Quadruplicate, 100 µl samples in 96-well pinchbar flat-bottomed 
polystyrene microtiter plates with lids (Nunc) were incubated for 48 h without 
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shaking at 37°C surrounded by distilled water to limit evaporation of samples. 
Nonadherent bacteria were then removed by washing twice with H2O prior to 
addition of crystal violet (150 µl of a 0.1% solution in water; Sigma-Aldrich). After 
10 min incubation at room temperature, the wells were rinsed twice with H2O and 
air-dried. Dimethyl sulfoxide (200 µl; Sigma-Aldrich) was added to each well, and 
the plates were shaken vigorously for 15 min on an orbital shaker to solubilize 
the dye, and A562 was measured using a Synergy HT multidetection microplate 
reader (BioTek Instruments, Inc.). Biofilms were also grown on glass coverslips 
for 48 h in 24-well tissue culture grade plates tilted at an angle to allow for a 
liquid-air interface to cross the coverslip. Biofilms grown on glass coverslips were 
visualized using a SZX10 stereomicroscope (Olympus) equipped with a QIClick 
Cooled Digital CCD camera (QImaging). 
 
Association, invasion, intracellular replication assays 
UTI89 was grown at 37°C for 48 h in static LB broth to induce type 1 pilus 
expression. Triplicate sets of confluent 5637 bladder epithelial cell monolayers 
grown in 24-well tissue culture plates were infected with UTI89 using a 
multiplicity of infection of ~15 bacteria per host cell. To facilitate and synchronize 
bacterial contact with the host cells, plates were centrifuged at 600 x g for 5 min 
at room temperature at the start of infection (Beckman Allegra 6 Centrifuge). 
Cells were infected in conjunction with chitosan (0.002% or 0.02%) for 2 h or 
corresponding volume of low pH phosphate buffer. After a 2 h incubation at 37°C, 
samples were washed three times with PBS containing Ca2+ and Mg2+ (PBS2+) to 
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remove any nonadherent bacteria. Wells for adherence and total growth assays 
were collected at this time point and lysed in PBS with 0.4% Triton X-100, and 
bacteria present within the lysates were enumerated by plating serial dilutions on 
LB agar plates. Monolayers for invasion and intracellular replication assays were 
then incubated for another 2 h with complete RPMI medium plus 100 µg/ml of 
gentamicin to kill extracellular bacteria. Monolayers for invasion assays were 
collected at this time (4 h) and processed as described above. Invasion was 
graphed as normalized to associated bacteria as well as raw values for invasion 
CFU. For intracellular replication assays, additional washes with PBS2+ were 
performed, followed by addition of fresh medium containing a lower concentration 
of gentamicin (10 µg/ml). Incubations were continued for another 14 h. This 
submaximal concentration of gentamicin was used to prevent extracellular 
growth of UPEC while limiting possible leaching of the antibiotic into the host 
cells during longer incubations. After final washes in PBS2+, host cells were again 
lysed as described above in PBS with 0.4% Triton X-100, with bacteria 
enumerated by plating serial dilutions on LB agar plates. 
 
Mouse infection 
Seven- to 8-week-old female CBA/J mice (Jackson Laboratory) were 
anesthetized via isoflurane inhalation and slowly inoculated via transurethral 
catheterization with 50 µl of a bacterial suspension (~107 CFU from 24 h static LB 
broth cultures of UTI89) in PBS as previously described. Bacterial reflux into the 
kidneys using this procedure is rare, occurring in less than 1% of the test animals 
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(unpublished data). Chitosan (0.01% in 50 µl of pH 4.5 phosphate buffer) was 
administered in a similar manner using transurethral catheterization of 
anesthetized mice for 20 min; however, mice were rotated 180° midway through 
the incubation to promote exfoliation of the entire bladder. At the appropriate time 
point, mice were sacrificed, bladders were harvested aseptically, weighed, and 
homogenized in 1 ml PBS containing 0.025% Triton X-100. Bacterial titers within 
the homogenates were determined by plating serial dilutions on LB agar plates. 
Eleven mice total, from two independent experiments, were used for each 
condition tested. Previous published results indicate no need for mock-infected 
mice to be housed in cages with the infected animals (3). 
 To determine the ability of UPEC to invade underlying tissues, mice were 
anesthetized and treated with chitosan. After 4 h of incubation, mice were 
infected as described above via transurethral catheterization. After 1 h of 
incubation, mice were sacrificed and bladders were aseptically removed, cut into 
quarters and incubated in 1 ml of gentamicin (100 µg/ml) for 1 h. Bladders were 
then washed and homogenized in the presence of 0.025% Triton X-100. After 
homogenization, bladders were serially diluted and titered as above.  
 To determine the contribution of mouse epithelial tissues to reservoir 
population, mice were infected and reservoir populations were allowed to 
establish for 3 d. At this time, mice were treated with chitosan or buffer. Post-
treatment, mice were sacrificed and bladders were rigorously washed with PBS 
to remove exfoliated superficial cells and lumen localized bacteria. Bladders were 
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then homogenized and titered to determine the relative contribution of tissue 
layers towards reservoir formation.  
 
Treatment efficacy 
Mice were infected as described above. At 3 days postinoculation, 
treatments were initiated by transurethral catheterization of mice with buffer or 
chitosan. A single dose of chitosan was administered on the first day of treatment 
(day 3) in conjunction with antibiotic treatment. Daily antibiotic treatment 
continued for 3 or 7 consecutive days. Gentamicin (200 µg) was given 
subcutaneously, while sparfloxacin (700 µg) and ciprofloxacin (40 µg) were given 
orally by gavage. Control animals were given water alone by oral gavage. All 
antibiotics were delivered in 50 µl volumes. Mice were sacrificed 3 days after the 
final antibiotic treatment. At this time point, bladders were harvested aseptically, 
weighed, and homogenized as described above, followed by serial dilution and 
titering of the bacteria. 
 
Mouse urine titers 
Mice were infected as described above. After allotted treatment regimen, 
urine was collected daily. Mice were placed over sterile saran wrap and allowed 
to urinate. Urine was collected, measured for volume, and plated on LB agar 
plates directly after dilution in PBS to 100 µl volume if required. We were unable 
to create a dilution range due to limited quantity of mouse urine, and thus all 
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colonies were counted when possible on LB plates. A count over 10,000 CFU/ml 
was designated as a recurrence event.  
 
SEM microscopy 
Infected mouse bladders were excised from animals, cut longitudinally into 
halves and fixed for 4 h at 4°C in a mixture of 4% paraformaldehyde and 2% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4). The tissue samples were 
rinsed in 0.1 M cacodylate buffer and postfixed in 1% osmium tetroxide in the 
same buffer for 1 h at 4°C. Specimens were critical point dried, sputter-coated 




P values were determined by Student’s t-test and Mann-Whitney U tests 
performed using Prism 5.01 software (GraphPad Software). Values of less than 
0.05 were defined as significant. 
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SMALL NONCODING RNAS REGULATE THE STRESS 
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Small noncoding RNA (sRNA) molecules can modulate diverse bacterial 
functions ranging from carbon metabolism to virulence gene expression. Here, 
we used a series of deletion mutants, each lacking one of seven conserved 
sRNAs (DsrA, RprA, OxyS, RyhB, MicF, MicC, and Spot 42) for effects on the 
fitness and virulence potential of the reference uropathogenic Escherichia coli 
(UPEC) isolate UTI89. UPEC strains are the primary etiologic agents of urinary 
tract infections, which consistently rank among the most common of infectious 
diseases. In broth culture, each sRNA deletion mutant grew like the wild type 
strain, whereas in biofilm assays all but the micC mutant exhibited modest, 
though significant defects. None of the mutants displayed increased sensitivity to 
nitrosative stress, but the Spot 42 (spf) and micC mutants were both markedly 
impaired in their ability to deal with oxidative stress generated by methyl 
viologen. The spf mutant, but not the others, also had diminished swim motility. 
Focusing further on Spot 42, we found that deletion of this sRNA significantly 
altered the levels of key metabolites in UTI89, including the coenzyme A 
precursor pantothenate. The spf mutant was also defective in its ability to multiply 
and persist within host bladder epithelial cells in both cell culture-based assays 
and in a murine infection model. Cumulatively, these results demonstrate that 
specific sRNA molecules can impact multiple bacterial processes that control the 
stress resistance and virulence capacity of UPEC both in vitro and within the host 
environment. 
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Introduction 
Small noncoding RNA (sRNA) molecules help control the translation and 
activity of numerous proteins in both nonpathogenic and pathogenic bacteria (7, 
55, 61, 81). Base pairing between an sRNA and cognate mRNA targets can 
either promote or, more often, inhibit translation. Oftentimes, sRNA-mRNA 
interactions are facilitated by the homohexameric RNA chaperone Hfq (12). 
sRNAs can modulate diverse bacterial functions, including metabolism, iron 
utilization, the expression of outer membrane proteins (OMPs), stress resistance, 
and virulence (15, 25, 61, 75). Much of what we currently know about sRNAs is 
based on work carried out with nonpathogenic K-12 Escherichia coli isolates. In 
these bacteria the expression of about 90 different sRNA species has been 
confirmed, with more than 200 additional sRNAs predicted by in silico analyses 
(59, 66, 67). Many of these sRNA molecules are also encoded by pathogenic E. 
coli strains, including diarrheagenic isolates and strains of uropathogenic E. coli 
(UPEC). Previously, we reported that deletion of hfq in the UPEC reference 
isolate UTI89 rendered this pathogen severely attenuated in its ability to colonize 
both the bladder and kidneys in a mouse urinary tract infection (UTI) model 
system (34). The hfq mutant was also hypersensitive to oxidative and nitrosative 
stresses and was defective in its ability to swim and form biofilms. These results 
indicate that sRNAs in association with Hfq contribute significantly to the fitness 
and virulence potential of UPEC.  
UTIs caused by UPEC are among the most common of infectious 
diseases worldwide, representing a daunting medical and financial burden that is 
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likely to worsen as antibiotic resistance among UPEC strains increases (23). 
Successful colonization of the urinary tract requires that UPEC deal with a 
panoply of stresses and host defenses, including the bulk flow of urine, nutrient 
limitations, the production of reactive nitrogen and oxygen radicals, the secretion 
of antimicrobial compounds, and the influx of phagocytes like neutrophils (26, 
50). Upon entering the lumen of the bladder, UPEC expressing filamentous 
adhesive organelles known as type 1 pili are able to bind and subsequently 
invade bladder epithelial cells, gaining at least temporary reprieve from 
extracellular antimicrobial factors and shear forces that work to eliminate 
microbes. Within bladder cells, UPEC enter into actin-bound, low pH endosomal 
compartments where they can persist quiescently for days to many weeks (21, 
49, 52). Alternatively, UPEC may break into the host cell cytosol where they can 
multiply, forming large intracellular biofilm-like communities (IBCs) in close 
association with cytokeratin intermediate filaments (31, 49). The persistence and 
dissemination of UPEC within the urinary tract is facilitated by multiple factors, 
including the formation and eventual dispersion of IBCs as well as flagella-driven 
motility and the optimized use of central metabolic pathways like 
gluconeogenesis and the TCA cycle (1, 26). The ability of UPEC to cope with 
changing environmental stresses within the host likely requires rapid alteration of 
metabolic and stress response pathways, tasks that can potentially be facilitated 
with the aid of sRNA molecules.   
Here, taking a candidate approach using isogenic deletion mutants, we 
assess the effects of a panel of seven Hfq-dependent sRNA molecules on the 
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fitness and virulence potential of UPEC, before focusing in greater detail on a 
single sRNA, Spot 42. 
 
Materials and Methods 
Bacterial strains and plasmids 
Strains used in this study are listed in Table 4.1. Mutant strains were 
constructed in the human cystitis isolate E. coli strain UTI89 using the primers  
listed in Table 4.2 and the lambda Red recombination system, as previously 
described (19, 51). Chloramphenicol and kanamycin resistance cassettes, each 
containing their own promoter and terminator, were amplified from Salmonella 
strain TT23216 or plasmid pKD4, respectively (19, 34). The primers for 
amplification of the cassettes were designed with overhanging ends containing 
~40 bp of homology to the 5’ and 3’ ends of target knockout sites. PCR products 
were then introduced by electroporation into UTI89 carrying pKM208, which 
encodes IPTG (isopropyl-b-D-thiogalactopyranoside)-inducible lambda Red 
recombinase (19). The spf and micC double knockout strain was constructed by 
deleting micC from UTI89∆spf using the kanamycin resistance cassette amplified 
from the plasmid pKD4. Knockout strains were verified by PCR amplification 
using primers specific to sequences flanking each target gene.  
The plasmids used in this study are listed in Table 4.1. Plasmids 
pMB1_GrxB, pMB2_Gsp, pMB3_PanC, and pMB4_YggE were constructed by 
PCR amplifying from UTI89 genomic DNA each gene of interest with flanking 
KpnI and PstI restriction digestion sites. PCR products were cut using KpnI and  
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Table 4.1 Bacterial strains and plasmids 
 
Strain or Plasmid Description Source or Reference 
Strains   
E. coli   
UTI89 UPEC reference strain and cystitis isolate (14, 49) 




UTI89∆dsrA UTI89 dsrA::cat This work 
UTI89∆micC UTI89 micC::cat This work 
UTI89∆micF UTI89 micF::cat This work 
UTI89∆oxyS UTI89 oxyS::cat This work 
UTI89∆rhyB UTI89 rhyB::cat This work 
UTI89∆rprA UTI89 rprA::cat This work 
UTI89∆spf UTI89 spf::cat This work 
UTI89∆spf∆micC UTI89 spf::cat, micC::kan This work 
UTI89∆fimH UTI89 fimH::cat T. Wiles 
TT23216 Template strain with Cat cassette flanked 
by universal primer sequences 
(34) 
Plasmids   
pGEN-GFP(LVA) Encodes destabilized GFP (half-life ~40 
min) under control of em7 promoter, Apr 
(81) 
pKD4 Template plasmid for use in lambda Red 
Recombination, Kanr 
(18) 
pKM208 IPTG-inducible lambda Red recombinase 
expression plasmid, Apr  
(52) 
pRR48 lacIq/ptac cloning vector, Apr (74) 
pMB1_GrxB grxB cloned into pRR48, Apr This work 
pMB2_Gsp gsp cloned into pRR48, Apr This work 
pMB3_PanC panC  cloned into pRR48, Apr This work 
pMB4_YggE yggE cloned into pRR48, Apr This work 
pACYC184 Low copy cloning plasmid, Clmr Tetr NEB 
pMB5_MiaA-Flag C-terminal Flag-tagged miaA cloned into 
pACYC184, Tetr 
This work 
pRRK1 Modified pRR48 lacking Shine-Delgarno 
sequence, Apr 
This work 
pSpot42a spf cloned into pRRK1, Apr This work 
pMicC1 micC cloned into pRRK1, Apr This work  
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Table 4.2 Oligonucleotides employed during the study 
 
















































Table 4.2 Continued 
 
























a F, forward primer; R, reverse primer; KO, knockout primer; Conf, 
confirmation primer. 
b Universal Primer sequence underlined 
c Added restriction sites underlined 
d Flag tag and linker sequence in bold 
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PstI restriction enzymes and ligated into pRR48 using T4 DNA Ligase (NEB)(70). 
pSpot42a and pMicC1 were similarly constructed using pRRK1, a derivative of 
pRR48 that lacks a ribosome binding site following the ptac promoter. To create 
pMB5_MiaA-Flag, the miaA gene in UTI89 was amplified, along with 200 base 
pairs upstream of the miaA start site, using primers that were designed to also 
incorporate flanking EcoR1 restriction sites and a C-terminal FLAG tag. The PCR 
product was ligated into the EcoR1 site in pACYC184 (NEB). Plasmid constructs 
were verified by sequencing. 
 
Growth assays 
UTI89 and its derivatives were grown from frozen stocks in either Luria-
Bertani (LB) broth, 100 mM morpholineethanesulfonic acid (MES)-buffered LB 
(LB-MES; pH 5.0), or modified M9 minimal medium (6 g/l Na2HPO4, 3 g/l 
KH2PO4, 1 g/l NH4Cl, 0.5 g/l NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 
0.0025% nicotinic acid, 0.2% casein amino acids, and 16.5 µg/ml thiamine in 
H2O) (Sigma-Aldrich) at 37°C overnight in loosely capped 20-by-150-mm 
borosilicate glass tubes at a 30º angle with shaking at 225 rpm. Overnight 
cultures were diluted 1:100 into 100-well honeycomb plates and assayed for 
growth using a Bioscreen C instrument (Growth Curves USA) as described (34). 
Growth was assessed in LB-MES ± 1 mM sodium nitrite and in LB broth ± 1 mM 
EDTA, 0.01% sodium dodecyl sulfate, or 1 mM methyl viologen (MV, Sigma-
Aldrich). Antibiotics were added to maintain plasmids as necessary for growth of 
overnight cultures, but not for subsequent growth assays (Sigma-Aldrich).  
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Superoxide dismutase (SOD) assays 
A superoxide dismutase detection kit was purchased from Cell 
Technologies, Inc. and used according to the manufacturers specifications. 
Briefly, UTI899 and UTI89∆spf were grown to OD600 of 0.1, 0.2, and 0.4 in LB 
broth + 1 mM MV, pelleted, and lysed in B-PER (Thermo Scientific) prior to 
analysis. The superoxide dismutase detection kit relies on the SOD-inhibitable 
conversion of a highly water-soluble tetrazolium salt (WST-1 (2-(4-Iodophenyl)- 
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)- 2H-tetrazolium monosodium salt) to a 
yellow WST-1 formazan dye upon reduction with superoxide anions produced by 
xanthine oxidase. Reduced production of the WST-1 formazan dye, as measured 
by assaying absorbance at 440 nm, correlates with increased SOD activity. 
Measurements were normalized to the OD600 of each bacterial culture sample 
just prior to collection.  
 
Motility assays 
Bacterial swimming motility was determined by inoculating 0.2% agar 
plates with a toothpick dipped into an overnight culture of each strain. Care was 
taken to break the surface but not touch the bottom of the plate, to avoid possible 
initiation of twitching motility. Plates were incubated face up at 37°C and bacterial 
spreading was measured at 2-h intervals for 10 h. Values are from three 
independent experiments done in triplicate. Swarm motility assays were 
performed using 0.5% Eiken agar plates supplemented with 0.5% glucose. Five 
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µL of bacteria were spotted on the surface of the plate and allowed to swarm 
overnight (16 h) at 37°C.  
 
Biofilm assays 
In vitro microtiter plate-based biofilm assays were performed as previously 
described (34). Bacteria were diluted 1:100 from overnight shaking cultures into 
modified M9 medium, and quadruplicate 100-ml samples added to 96-well 
pinchbar flat-bottomed polystyrene microtiter plates (Nunc) were incubated with 
lids for 48 h without shaking at 30°C.  Sample-containing wells were surrounded 
by wells with H2O only to minimize evaporation. Nonadherent bacteria were 
removed by washing twice with H2O prior to addition of crystal violet (150 µl of a 
0.1% solution in water; Sigma-Aldrich). After a 10-min incubation at room 
temperature, the wells were rinsed twice with H2O and air-dried. Dimethyl 
sulfoxide (200 µl; Sigma-Aldrich) was then added to each well, and the plates 
were shaken vigorously for 15 min on an orbital shaker to solubilize the dye. A562 
was measured using a Synergy HT multidetection microplate reader (BioTek 
Instruments, Inc.).  
 
Mouse infections 
Seven- to 8-week-old female CBA/J mice (Jackson Laboratory) were 
anesthetized using isoflurane inhalation and slowly inoculated via transurethral 
catheterization with 50 µl of bacteria (~107 CFU from 24 h static LB broth 
cultures) resuspended in PBS as previously described (34). Bacterial reflux into 
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the kidneys using this procedure is rare, occurring in less than 1% of the test 
animals (unpublished data). At 6 h, 1 d, 3 d, or 9 d postinoculation, mice were 
sacrificed and bladders were harvested aseptically, weighed, and homogenized 
in 1 ml PBS containing 0.025% Triton X-100. Bacterial titers within the 
homogenates were determined by plating serial dilutions on LB agar plates. 
Eleven mice total, from two independent experiments, were used for each 
condition tested. Numbers of intracellular bacteria present at the 6 h time point 
were determined using an ex vivo gentamicin protection assay as described (65). 
Reservoir populations of UPEC within bladder tissues were enumerated as 
previously described (9). Briefly, at 3 d post-inoculation mice were treated for 3 
consecutive days with gentamicin (200 µg in 50 ml delivered subcutaneously) in 
order to sterilize the urine and kill any extracellular bacteria. Control animals 
received subcutaneous injections of PBS. Mice were sacrificed 3 d after the final 
antibiotic treatment and bacterial titers within the bladder were determined as 
described above. Competition experiments were performed as described (1), 
using a final inoculating dose of 107 CFU with equal numbers of wild type and 
mutant bacteria.  
 
IBC quantification 
CBA/J mice were infected with UTI89/pGEN_GFP(LVA) or 
UTI89∆spf/pGEN_GFP(LVA) via transurethral catheterization. Six h post-
inoculation, mice were sacrificed and bladders were removed, halved, splayed, 
and pinned down lumenal side up on silicon disks (Sylgard 184 silicone 
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elastomer, Dow Corning Corp.) under Ringer solution [5 mM NaCl, 3 mM HCl, 2 
mM CaCl2, 1 mM MgCl2, 3 mM NaH2PO4, 10 mM glucose, and 5 mM Hepes 
(pH 7.4)]. GFP positive IBCs were visualized and enumerated using a SZX10 
stereomicroscope (Olympus) equipped with a Canon PowerShot A640 10.1 
megapixel camera mounted via a Camadapter kit (camadapter.com). 
 
Metabolomics 
Chemicals and reagents were of the highest purity and purchased from 
Sigma-Aldrich, except for MSTFA (N-methyl-N-(trimethylsilyl) trifluoroacetamide), 
which was purchased from Thermo Scientific, and methoxyamine hydrochloride, 
which was purchased from MP Biomedicals (Solon, OH). Six biological replicates 
of each strain were used per experiment. Cultures were grown to an OD600 of 
1.0, pelleted by centrifugation, and frozen. Pellets were resuspended in 5 ml of 
boiling 75% EtOH (aqueous), vortexed, and then incubated at 90°C for 5 min. 
Cell debris was removed by centrifugation at 5000 x g for 3 min. Supernatant 
were transferred to new tubes and dried en vacuo. 
GC-MS analysis was performed using a Waters GCT Premier mass 
spectrometer fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 
autosampler. Dried samples were suspended in 40 µl of a pyridine solution 
containing 40 mg/ml O-methoxylamine hydrochloride and incubated for 1 h at 
30°C. Twenty ml of each sample was transferred to an autosampler vial and 
incubated with MSTFA for 30 min at 37°C with shaking. One ml of sample was 
injected into the inlet, which was held at 250°C. The gas chromatograph was 
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obtained using an initial temperature of 95°C for 1 min followed by a 40°C/min 
ramp up to 110°C, with a hold time of 2 min. This was followed by a second 
5°C/min ramp up to 250°C, and then a third ramp up to 350°C, with a final hold 
time of 3 min. A 30 m Restek Rxi-5 MS column with a 5 m long guard column 
was employed for analysis. Data were collected using MassLynx 4.1 software 
and analysis of known metabolites was performed using QuanLynx. To identify 
unknown metabolites, data from peaks that were picked using MarkerLynx and 
exported to SIMCA-P (ver. 12.0.1), where principal component analysis and 
partial least squares - differential analysis was performed.  
 
Adhesion, invasion, and intracellular replication assays 
Bacteria were grown at 37°C for 48 h in 20 ml static LB broth to induce 
type 1 pilus expression. Cultured 5637 bladder epithelial cells (ATCC HTB-9) 
were grown in RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone, 
Logan, UT) at 37°C with 5% CO2. Triplicate sets of confluent 5637 bladder 
epithelial cell monolayers in 24-well tissue culture plates were infected using a 
multiplicity of infection of ~15 bacteria per host cell. To facilitate and synchronize 
bacterial contact with the host cells, plates were centrifuged at 600 x g for 5 min 
at room temperature using a Beckman Allegra 6 Centrifuge. After a 2-h 
incubation at 37°C, samples were washed three times with PBS containing Ca2+ 
and Mg2+ (PBS2+) to remove any nonadherent bacteria. For adherence assays, 
host cells were lysed at this point by addition of PBS containing 0.4% Triton X-
100. For invasion assays, the monolayers were incubated prior to lysis for an 
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additional 2 h in complete RPMI medium with 100 µg/ml of gentamicin added to 
kill any extracellular bacteria. For intracellular growth/persistence assays, after 
the 2-h incubation with medium containing 100 µg/ml gentamicin, infected 
monolayers were washed with PBS2+ and fresh medium containing 10 µg/ml 
gentamicin was added. This submaximal concentration of gentamicin was used 
to prevent extracellular growth of UPEC while limiting possible leaching of the 
antibiotic into the host cells during longer incubations (49). After an additional 14-
h incubation, monolayers were washed with PBS2+ and lysed. Bacteria present in 
the lysates recovered during these assays were enumerated by plating serial 
dilutions on LB agar plates. 
 
Statistical analysis 
P values were determined by Student’s t tests or by Mann-Whitney U tests 
performed using Prism 5.01 software (GraphPad Software). Values of less than 
0.05 were defined as significant. 
 
Results and Discussion 
Construction of sRNA deletion mutants 
The sRNAs chosen for analysis in this study are well conserved among K-12 E. 
coli and UPEC isolates, and several have been implicated as important 
regulators of gene expression in closely related Salmonella strains (24, 54, 57, 
74).  Each of the sRNAs examined here are known to target one or more mRNAs 
(Table 4.3). Two of the sRNAs (DsrA and RprA) promote expression of the  







Table 4.3 Tested sRNA molecules 
 




Known Targets* Reference 
DsrA 86 100 H-NS, rpoS, gadAX, 
hdeAB, gadBC, ehxCABD 
(36-38, 41, 
68) 
RprA 104 100 rpoS, csgD, ydaM  (40, 46) 
OxyS 109 100 fhlA, rpoS, yhiV, yhiM, 
gadB, dps, uhpT, pqqL 
(2, 3, 79) 
Spot 42 108 100 galK, gsp, dppB, fucK, fucI, 
ebgC, gltA, maeA, glpF, 
sthA, nanC, srlA, xylF, 
ascF, atoD, caiA, fucP, 
paaK, puuE 
(7, 8, 47) 
RyhB 89 100 sdhCDAB, acnA, fumA, 
ftnA, bfr, sodB, sodA, cysE, 
entCEBAH, iscRSUA, 
fdoG, nuoA 
(43) (20, 63, 
72) (6) 
MicC 108 97 ompC, ompD (13, 56) 
MicF 92 99 ompF, lrp, yahO, lpxR (5, 17, 29) 
* Genes in bold indicate targets that are activated by the indicated sRNA, all 
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stationary-phase sigma factor RpoS, while another (OxyS) inhibits RpoS 
synthesis (60). The sRNA MicC acts to repress the synthesis of OmpC and 
OmpD, while the sRNA MicF interferes with OmpF expression (4, 13). Recent 
work indicates that MicF can also repress translation of the global transcriptional 
regulator Lrp, the periplasmic protein YahO, and the lipid A-modifying enzyme 
LpxR (17, 29). The sRNA RyhB helps regulate iron homeostasis (43), and the 
archetypal sRNA Spot 42 (spf) is known to modulate basal metabolic processes 
in coordination with the global regulators CRP and cAMP (7, 8). Spot 42 is an 
abundant sRNA in both K-12 E. coli strains and the UPEC isolate UTI89 ((62) 
and manuscript in preparation), and when induced to high levels can affect the 
activities of other sRNA molecules by competing for Hfq binding sites (48, 62). 
Each of these seven conserved sRNAs was deleted individually in the UPEC 
reference strain UTI89 using the lambda-Red recombination system. Mutants 
were verified by PCR analysis and tested against the wild type strain in a series 
of in vitro experiments (Fig. 4.1). 
 
sRNA-mediated regulation of biofilm formation by UPEC 
All of the sRNA deletion mutants grew normally in standard LB broth and 
in modified M9 minimal medium (Fig. 4.1A and data not shown). Likewise, all 
mutants grew like wild type UTI89 in the presence of the divalent cation-chelating 
agent EDTA (1 mM) or the surfactant sodium dodecyl sulfate (0.01%) (data not 
shown). Each mutant also expressed wild type levels of type 1 pili, as determined 
by yeast agglutination assays, and each was similarly hemolytic on blood agar  














Figure 4.1 sRNAs modulate biofilm formation, swim motility, and stress 
resistance of UTI89  
 
(A) Growth of a wild type UTI89 and isogenic sRNA deletion mutants in LB broth. 
(B) Biofilm formation by UTI89 and its derivatives was measured following growth 
in modified M9 medium at 30°C in microtiter plates.  (C) Quantitation of swim 
motility over the course of 10 h at 37°C. Motility of the spf mutant is shown 
separately in (D) for clarity. Graphs in (E) and (F) show growth curves of UTI89 
and the sRNA mutants in MES-LB broth + 2 mM ASN and in LB broth + 1 mM 
MV, respectively. Data in B-D represent the mean ± SE of at least three 
independent experiments performed in triplicate or quadruplicate. P values were 
determined by Student’s t test; *P<0.05, **P<0.01, ***P<0.001, versus the wild 
type control. Graphs in A, E, and F show the means of triplicate samples from 
representative experiments carried out three or more times. Error bars in these 
graphs were negligible. 
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plates, indicating normal secretion of the UPEC-associated pore-forming toxin a-
hemolysin (data not shown). In microtiter plate-based biofilm assays carried out 
at 37°C all of the sRNA knockout mutants behaved like the wild type strain, but at 
30°C, where biofilm formation by UPEC is generally more robust, all of the sRNA 
mutants, aside from ∆micC, were at least modestly defective (Fig. 4.1B). In these 
assays, the ∆oxyS mutant was the most attenuated in biofilm development, a 
phenotype that may be in part attributable to the misregulation of OxyS targets 
like RpoS (80). Deletion of the sRNAs DsrA and RprA can also disrupt the 
balance of RpoS regulation, and could thereby compromise biofilm formation (22, 
44). In addition, RprA may modulate the development of biofilms by UTI89 via 
effects on the stationary phase-induced biofilm regulator CsgD and the 
diguanylate cyclase YdaM (46).   
 
Spot 42 promotes the motility of UPEC 
Motility of the sRNA mutants was assessed using both swarm and swim 
assays. All strains behaved similarly on swarm motility plates, and all but the 
∆spf mutant displayed wild type swimming phenotypes (Fig. 4.1C and D, and 
data not shown). In these swim motility assays, UTI89∆spf consistently lagged 
behind the wild type strain by about 1 h. Interestingly, a recent microarray-based 
study implicated Spot 42 as a negative regulator of motility and chemotaxis in the 
salmon pathogen Aliivibrio salmonicida (27), indicating that Spot 42 homologues 
can have divergent effects on bacterial behavior across species.  
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Spot 42 and MicC enhance UPEC resistance to oxidative 
stress 
Nitrosative and oxidative stresses are known to play important roles in the 
host response to myriad infections, including UTIs (30, 35, 39, 58). The effect of 
nitrosative stress on growth of the sRNA mutants was investigated using acidified 
sodium nitrite (ASN), which produces nitrous acid, NO and other reactive 
nitrogen species upon addition to LB-MES broth (pH 5.0) (78). Sensitivity to 
oxidative stress was tested using MV, which generates superoxide radicals in LB 
broth culture (28). All of the strains grew similarly in LB-MES with or without 2 
mM ASN (Fig. 4.1E and data not shown). In contrast, the micC and spf mutants 
had clear and highly reproducible growth defects in the presence 0.5, 1, and 2 
mM MV (Fig. 4.1F and data not shown). Complementation using a plasmid 
encoding spf driven by a pTac promoter rescued growth of the spf mutant in the 
presence of MV (Fig. 4.2A). The micC mutant could be similarly complemented, 
dependent upon the level of induction by IPTG (Fig. 4.2B).  
A double knockout lacking both spf and micC rendered UTI89 more 
sensitive to MV than either single deletion alone, suggesting that these two 
sRNAs promote oxidative stress resistance via effects on independent pathways, 
potentially involving multiple targets (Fig. 4.2C). For example, by repressing the 
translation of OmpD and OmpC, MicC can alter the permeability of the bacterial 
envelope to MV and other damaging radicals (13, 53, 64). Likewise, Spot 42 
might decrease the porosity of the bacterial envelope to oxygen radicals via its 
ability to repress translation of a number of transporters, permeases, and porin- 

















Figure 4.2 Spot 42 and MicC modulate oxidative stress resistance in UTI89  
 
The strains indicated in (A-C) were grown shaking in plate format at 37°C in LB 
broth + 1 mM MV, and optical density (OD600) measurements over time were 
obtained using a Bioscreen C instrument. Strains carrying the empty vector 
pRRK1 served as controls. In (A), Spot42 expression from the pSpot42a plasmid 
was induced by addition of 1 mM IPTG. To complement the micC mutant in (B), a 
range of IPTG concentrations, in 10-fold increments from 10 to 1000 mM, was 
used to induce MicC expression. Leaky expression of MicC was sufficient to 
complement growth of UTI89∆micC, while increasing concentrations of IPTG 
negatively affected growth. Each curve (A-C) represents the means of 
quadruplicate samples, and are representative of experiments performed three or 
more times. (D) SOD activity of UTI89 and UTI89∆spf following growth in LB 
broth + 1 mM MV. Measurements were normalized to the OD600 of each culture 
taken just before collection, and represent the means ± SE of three independent 
experiments performed in triplicate. P values were determined by the Student’s t 
test; ***P<0.001, versus wild type UTI89. 
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like molecules, including AscF, GlpF, SlrA, NanC, FucP, and XylF (see Table 
4.3) (7, 8).  
Spot 42 and MicC could also influence the sensitivity of UTI89 to oxidative 
stress independent of effects on the bacterial envelope. For example, focusing 
on just Spot 42 with its broader range of known and predicted mRNA targets, we 
observed that, in the presence of 1 mM MV, UTI89∆spf had significantly reduced 
SOD activity relative to the wild type strain (Fig. 4.2D). Spot 42 is not known to 
regulate the expression of any SOD enzymes, although the web-based tool 
TargetRNA predicts that Spot 42 may base pair with mRNA encoding the tRNA 
prenyltransferase MiaA, which we found does positively influence the resistance 
of UPEC to oxidative stress (unpublished observations, (71)). However, the use 
of reporter constructs has so far failed to establish miaA as a bona fide target of 
Spot 42. Additional in silico analyses indicated that Spot 42 might bind messages 
for the oxidative stress defense protein YggE and the atypical glutaredoxin Grx2, 
while a recent microarray-based study suggested that Spot 42 promotes the 
expression of the glutathionylspermidine synthetase/amidase fusion protein Gsp 
(7). Each of these gene products has the potential to enhance bacterial 
resistance to oxidative stress (16, 33, 73), but overexpression of recombinant 
YggE (pMB4_YggE), Grx2 (pMB1_GrxB) or Gsp (pMB2_Gsp) did not rescue 
growth of UTI89Dspf in the presence of MV (data not shown). It is feasible that 
the combined effects of multiple Spot 42 targets dictate the sensitivity of UTI89 to 
MV. Interestingly, the spf mutant grew like wild type UTI89 in the presence of 
other oxidative stressors, including H2O2 (0.6 mM), menadione (40 mg/ml), 
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cumene hydroperoxide (25 mM), and plumbagin (0.05 mM) (data not shown), 
suggesting that Spot 42 does not alter UPEC resistance to all forms of oxidative 
stress. This sort of selective susceptibility of a mutant E. coli strain to different 
types of oxidative stress has been noted previously (e.g., glutaredoxin mutants) 
(73).  
 
Altered metabolism of UTI89∆spf 
Spot 42 can help fine-tune the regulation of central and secondary 
metabolic processes in K-12 laboratory-adapted strains of E. coli (7, 8, 47). 
Taking a metabolomics approach employing gas chromatography coupled with 
mass spectroscopy to measure levels of 47 common metabolites in UTI89 and 
UTI89∆spf, we found evidence that Spot 42 can also affect key metabolic 
processes in UPEC. Following growth in LB broth to an OD600 of 1.0, UTI89∆spf 
had significantly reduced levels of lactate, 2-phosphoglycerate, and 
pantothenate, but higher levels of ribose, 2-hydroxyglutarate, and b-alanine (Fig. 
4.3, see also Supplemental Fig. 4.1)). These changes suggest broad 
irregularities in carbon utilization by the spf mutant, potentially impacting 
glycolysis, fatty acid metabolism, and the pentose phosphate pathway, among 
others. At the root of these irregularities may be the decreased ability of 
UTI89∆spf to efficiently convert b-alanine into pantothenate, the direct precursor 
of the acyl carrier Coenzyme A (CoA). Decreased levels of CoA can affect 
multiple metabolic processes, including the generation of reducing equivalents 
like NADH. Deficiencies in the production of nicotinamide adenine dinucleotide 
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(NADH) may contribute to the increased sensitivity of UTI89∆spf to MV (see Fig. 
4.1F). However, induced expression of the pantothenate synthetase PanC, which 
catalyzes the conversion of b-alanine and pantoate into pantothenate (18), was 
not sufficient to restore wild type growth of the spf mutant in the presence of MV 
(data not shown). Of note, the altered abundance of CoA precursors measured in 
UTI89∆spf is not attributable to spurious turnover of acetyl-CoA by the 
chloramphenicol acetyltransferase enzyme encoded by this mutant, as another 
mutant (UTI89∆fimH) carrying the same antibiotic resistance cassette was 
indistinguishable from the wild type strain with respect to its metabolomics profile. 
 
Spot 42 regulates the intracellular persistence of UTI89 
Interactions between UTI89∆spf and host cells were initially assessed 
using the human bladder epithelial cell line known as 5637. In these cell culture-
based assays, the spf mutant associated with the bladder cells in higher numbers 
than wild type UTI89, but both mutant and wild type strains invaded the host cells 
with similar frequencies (Fig. 4.4A - B). Over extended 14-h assays, UTI89∆spf 
displayed a reduced ability to persist within the bladder cells (Fig. 4.4C).  
These experiments were complemented using a well-established murine 
UTI model in which adult female CBA/J mice were infected via transurethral 
catheterization (9). In non-competitive assays, similar numbers of wild type 
UTI89 and UTI89∆spf were recovered from bladders at 6 h, 1 d, and 3 d post-
inoculation (Fig. 4.5A-C). Both strains were also able to colonize bladders 
similarly at the 3 d time point in competitive assays, in which equal numbers of  






Figure 4.3 Deletion of spf alters key metabolic processes in UTI89  
 
The abundance of 47 common metabolites in UTI89 and UTI89∆spf was 
determined using gas chromatography in association with mass spectroscopy. 
Only metabolites that were significantly different between the wild type and 
mutant strain are shown. Data are presented as the means ± SD of 6 
independent replicates. *P<0.05 for all UTI89∆spf samples versus wild type 































































Figure 4.4 Spot 42 modulates interactions between UTI89 and host bladder 
cells  
 
(A) UTI89∆spf associates with cultured bladder epithelial cells at higher levels 
than wild type UTI89. (B) Both mutant and wild type strains invade the host cells 
similarly, (C) but over the course of a 14-h assay in the presence of gentamicin 
the spf mutant is less able to persist intracellularly. Data are expressed relative to 
wild type UTI89 as the means ± SD of three or more experiments performed in 
triplicate. *P<0.05 or ***P<0.001, versus the wild type control as determined by 




















































































Figure 4.5 Spot 42 promotes the intracellular persistence of UTI89 in a 
murine model of UTI  
 
Adult female CBA/J mice were inoculated via transurethral catheterization with 
107 CFU of UTI89 or UTI89∆spf. (A-C) Bacterial titers in bladders were 
determined at 6 h, 1 d, and 3 d postinoculation. (D) For competitive assays in 
which mice were infected with equal numbers of the wild type and mutant strains 
(107 CFU total), bladder titers were calculated at the 3 d time point. (E) Numbers 
of intracellular bacteria were determined at 6 h postinoculation using ex vivo 
gentamicin protection assays. (F) IBCs were visualized and enumerated by 
fluorescent microscopy of splayed bladders recovered at 6 h postinoculation with 
strains carrying pGEN_GFP(LVA). (G) Bladder-associated UPEC reservoirs were 
assessed at 8 d postinoculation, three days after a 3-d systemic treatment with 
gentamicin. Bars denote median values for each group. *P<0.05, as determined 
using the Mann-Whitney U test. Graphs depict cumulative results from two 
independent assays (n = 11 mice per group).  
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UTI89 and the spf mutant were co-inoculated into the same mice (Fig. 4.5D). 
When examining just the intracellular, gentamicin-protected pool of bladder-
associated bacteria at the 6 h time point in noncompetitive assays, UTI89∆spf 
had a clear defect that corresponded with reduced numbers of IBCs (Fig. 4.5E - 
F). The decreased levels of intracellular UTI89∆spf detected during the acute 
phase of infection correlated with notably decreased levels of gentamicin-
protected intracellular reservoirs within the bladder tissue at 9 d postinoculation 
(Fig. 4.1G). In total, these data indicate that the spf mutant is diminished in its 
ability to persist and replicate within intracellular niches. 
 
Concluding remarks 
Over the past several years sRNAs have received much attention as 
important regulators of bacterial metabolic processes and stress response 
pathways, but the functional relevance of sRNA molecules to wild type E. coli 
isolates, including pathogenic strains, has remained largely unexplored. Results 
presented here demonstrate that specific sRNAs can alter the fitness and 
pathogenic behavior of UPEC. Six of the seven sRNA mutants tested had 
significant defects in biofilm formation, in line with previous observations using K-
12 E. coli strains and other bacterial isolates (11, 22, 32, 42, 45, 76). Biofilm 
formation by UPEC, both within bladder epithelial cells and on the bladder 
surface, likely facilitates bacterial persistence and eventual dissemination within 
the urinary tract (26). Interestingly, it has been noted that UPEC isolates that are 
prone to cause relapsing UTIs in women are often more adept than other UPEC 
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strains at forming biofilms in microtiter plate-based assays at 30°C (69). Our 
findings indicate that sRNAs can significantly affect the ability of UPEC to form 
biofilms, and may thereby impact the pathogenesis of UTIs. This possibility is 
supported by results obtained using the spf mutant. In vitro, UTI89∆spf has a 
modest, but significant, defect in biofilm formation that corresponds with the 
decreased capacity of this mutant to form IBCs and to persist within bladder 
epithelial cells. These deficiencies may also be influenced by the increased 
sensitivity of this mutant to oxidative stress, which is likely encountered during 
the course of a UTI. Furthermore, misregulation of key metabolic processes, 
including the biosynthesis of the CoA precursor pantothenate, could compromise 
the fitness of UTI89∆spf within the urinary tract via effects on multiple systems, 
including carbon utilization pathways and the generation of NADH and other 
reducing equivalents.  
The specific mRNA targets of Spot 42 that regulate fitness and virulence-
associated phenotypes in UTI89 were not discernable in our assays. It is feasible 
that each of the phenotypes observed with UTI89∆spf are associated with 
impaired regulation of multiple Spot 42 targets, as well as with altered activity of 
the Hfq chaperone in absence of the potential buffering effects of Spot 42 (48). It 
is likely that additional sRNA molecules, including those tested here using in vitro 
assays, also modulate the fitness and virulence of UPEC within host 
environments. Defining these sRNAs and their relevant targets will help better 
delineate the regulatory networks that are critical to the ability of UPEC to 
colonize the host and cause disease.  
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Figure 4.S1 Metabolic profile of UTI89 and UTI89∆spf  
 
The relative levels of 45 individual metabolites from stationary phase UTI89 and UTI89∆spf as 
determined by GC/MS. *=P<0.05 as calculated by Student’s t-test. 
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Abstract 
Uropathogenic Escherichia coli (UPEC) are the primary etiologic agents of 
urinary tract infections (UTIs), representing a tremendous global healthcare 
burden. Previous work demonstrated that the RNA chaperone Hfq and a handful 
of conserved, small, non-coding RNAs (sRNAs) can regulate stress responses 
and the virulence potential of UPEC. Despite the apparent importance of sRNAs 
to UPEC, the complete sRNA repertoire encoded by any UPEC isolate remains 
largely uncharacterized, with only conserved sRNA candidates from K-12 strains 
currently recognized. This manuscript describes initial efforts in identifying and 
characterizing the sRNA repertoire within the reference UPEC isolate UTI89 
using RNA-Seq. RNA was collected from UTI89 in mid-log and stationary phase 
growth, following exposure to nitrosative and oxidative stresses, and after 
infection of mouse bladders. RNA-Seq results indicate a plethora of candidate 
sRNA molecules, including nearly all of the conserved sRNAs previously 
identified in non-pathogenic K-12 strains. Individual deletion of several novel 
sRNA candidates had no effect on growth of UTI89 in broth culture, but many did 
have modest effects on biofilm formation. One of these, a candidate sRNA 
designated as UsrB, appeared to negatively affect the ability of UTI89 to colonize 
the mouse urinary tract, although this effect was subtle. This work represents the 
first steps towards defining the sRNA repertoire encoded by UPEC, opening the 
door to their further functional characterization as regulators of bacterial 
pathogenesis within the urinary tract.  
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Introduction 
Bacterial, small noncoding RNAs (sRNAs), first identified in K-12 strains of 
Escherichia coli, range in size from 50-500 nucleotide (nt) and are thought to 
broadly influence prokaryotic gene expression (21). Genomically, sRNAs are 
often located within intergenic regions and contain a specific promoter and ρ-
independent terminator, which initially facilitated their identification via 
computational approaches (Table 5.1) (2, 9). Through imperfect base-pairing with 
cognate messenger RNA sequences, sRNAs typically repress translation, but in 
some cases promote translation, acting as posttranscriptional regulators that 
fine-tune gene expression (46). In order to regulate target mRNA sequences, 
sRNAs utilize mechanisms of repression through mRNA degradation or blocking 
of ribosome binding sites (21, 42). Alternatively, sRNAs can stabilize mRNA 
molecules and release repressive secondary structure through anti-antisense 
mechanisms (18). sRNAs exert influence over multiple cellular processes, 
ranging from basal metabolism and quorum sensing to stress responses (1, 4, 
10). Historically, sRNAs were identified as abundant, low molecular weight RNA 
species on polyacrylamide gels; however, with the recent advent of deep 
sequencing technologies such as RNA-Seq, many more sRNAs are being 
discovered (Table 5.1) (41, 45, 47). The most recent count of validated sRNAs 
identified in the E. coli K-12 laboratory strain MG1655 is greater than 100, with 
>200 still to be verified (47). Although impressive, the number of sRNAs only 
hints at the diversity and breadth of functionality likely attributable to sRNAs.   
	  	   	  








Method Role in 
Virulence 
Year Ref. 
Escherichia coli 24 14/23 Bioinformatics NR 2001 (2) 
Escherichia coli 144 7/8 Bioinformatics NR 2002 (9) 
Escherichia coli 34 7/34 cDNA 
Sequencing 
NR 2003 (61) 
Listeria 
Monocytogenes 
3 3/3 Hfq Pull-down 
and Sequencing 
NT 2006 (13) 
Pseudomonas 
aeruginosa 
341 17/31 Bioinformatics NT 2006 (29) 
Sinorhizobium 
meliloti 
64 14/64 Bioinformatics 
and Tiling Array 
NR 2007 (58) 
Sinorhizobium 
meliloti 
32 8/32 Bioinformatics NR 2007 (17) 
Salmonella enterica 31 10/10 Hfq Pull-down 
and Deep 
Sequencing 
NT 2008 (49) 
Sinorhizobium 
meliloti 
60 14/18 Bioinformatics NR 2008 (59) 
Pseudomonas 
aeruginosa 
43 8/43 Bioinformatics NT 2008 (20) 
Caulobacter 
crescentus 
27 23/27  Tiling Array NT 2008 (26) 
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11 2/2 cDNA 
Sequencing 
NT 2008 (50) 
Salmonella 
typhimurium 
28 19/28 Bioinformatics Yes 2008 (35) 
Streptomyces 
coelicolor 
20 6/20 Bioinformatics NT 2008 (53) 
Streptomyces 
strains 
32 20/32 Bioinformatics NT 2008 (36) 
Mycobacterium 
tuberculosis 
9 9/9 Sequencing NT 2009 (3) 
Vibrio cholerae 2140  16/23 Deep 
Sequencing 
NT 2009 (28) 
Group A 
Streptococus 
40 16/32 Tiling Array NT 2009 (37) 
Streptomyeces 
griseus 
54 17/54 Bioinformatics NT 2009 (54) 
Staphylococcus 
aureus 
71 16/18 Deep 
Sequencing 
NT 2010 (6) 
Streptococcus 
pneumoniae 
50 13/14 Tiling Array NT 2010 (25) 
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24 2/2 Sequencing and 
Bioinformatics 
NT 2010 (38) 
Helicobacter pylori 60 60/60 Deep 
Sequencing 
NT 2010 (45) 
Streptococcus 
penumoniae 
40 10/40 Bioinformatics No 2010 (57) 
Sinorhizobium 
meliloti 
1125 6/6 Deep 
Sequencing 
NR 2010 (43) 
Xanthomonas 
campestris 
7 4/4 cDNA Cloning NT 2010 (22) 
Xanthomonas 
oryzae 
63 8/10 Tiling Array NT 2011 (27) 
Enterococcus 
faecalis 
12 10/11 Tiling Array NT 2011 (48) 
Streptomyces 
coelicolor 
63 14/24 Deep 
Sequencing 
NT 2011 (60) 
Clostridium strains >200 26/72 Bioinformatics No 2011 (12) 
Listeria 
monocytogenes 
150 4/4 Deep 
Sequencing 
Yes 2011 (31) 
Yersinia 
pseudotuberculosis 
150 29/49 Deep 
Sequencing 
Yes 2011 (23) 
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Method Role in 
Virulence 
Year Ref. 
Escherichia coli 171 10/17 Deep 
Sequencing 
NR 2011 (40) 
Bradyrhizobium 
japonicum 
7 7/7 Deep 
Sequencing 
NR 2012 (30) 
Agrobacterium 
tumefaciens  
228 22/X Deep 
Sequencing 
NT 2012 (64) 
Yersinia pestis  37 10/10 cDNA Cloning NT 2012 (39) 
1Identified in previous study 
NT = not tested; NR = not relevant, X = unknown  
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In addition to regulation of stress response and metabolism, sRNAs are 
known to influence host-pathogen interactions by modulating virulence potential 
in pathogens. Specifically, sRNAs can regulate aspects of invasion and 
colonization, as represented by the pathogenicity island-associated sRNA, IsrM. 
In Salmonella enterica, IsrM targets Salmonella Pathogenicity Island-1 effectors 
to promote invasion of, and intracellular replication within, host cells (19). 
Similarly, 6 of the 84 known sRNAs in S. enterica were shown to be expressed 
during non-replicative habitation of fibroblasts, suggesting that these sRNAs 
influence the in intracellular survival of this pathogen (34). In Staphylococcus 
aureus, SprD, another pathogenicity island-associated sRNA, directly represses 
Sbi, an immune-evasion molecule involved in dampening host responses (7). 
Despite this interaction, SprD positively affects the outcome of infection, 
indicating multiple opposing effects on S. aureus virulence. sRNAs also directly 
affect virulence factor expression levels, as exhibited in the plant pathogen 
Xanthomonas campestris in regards to the expression of the master virulence 
regulators, HrpX and HrpG (44). Finally, many sRNA functions appear to be 
conserved among pathogens, as shown in Yersinia pseudotuberculosis, where 
sRNAs that promote infection in a mouse model of yersinosis also control 
aspects of Yersinia pestis infection during plague (23). Collectively, these studies 
provide evidence that sRNAs can regulate pathogenesis by controlling 
expression of virulence factors, immune evasion molecules, and global 
transcriptional regulators in a broad range of pathogens.   
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Previous work in our lab directly linked the RNA chaperone Hfq to stress 
resistance and virulence in uropathogenic Escherichia coli (UPEC), the primary 
etiologic agent of urinary tract infections (UTIs) (24). Hfq is required for trans-
acting sRNA function in nearly all tested cases, where it promotes sRNA stability 
and protects against sRNA degradation by RNAses such as polynucleotide 
phosphorylase (16, 62). Chromosomal deletion of Hfq resulted in diminished 
stress resistance to redox stressors and the antimicrobial peptide, polymixin B 
(24). Bacteria lacking Hfq also exhibited decreased in vitro biofilm formation and 
virulence in a murine model of UTI. The observed Hfq effects on bacterial 
behavior were postulated to be due to dysfunctional sRNA action and were 
explored further in a follow up study characterizing UPEC sRNAs conserved from 
K-12 E. coli strains. The follow-up screen in UPEC illustrated a role for several 
sRNAs in biofilm formation, stress response and virulence. Of particular interest 
was a specific function for the sRNA Spot 42 in regulation of intracellular survival 
in a murine model of UTI (Submitted). Spot 42, and MicC, a regulator of the outer 
membrane porin OmpC, also contributed to oxidative stress responses upon 
challenge with the superoxide regenerator methyl viologen (MV), partially 
explaining several observed defects in an Hfq knockout strain. Collectively, these 
results led us to hypothesize that the UPEC sRNA repertoire likely contributes to 
the regulation of a wide-range of stress response and virulence signaling events 
during UTI.  
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Results 
RNA-Seq experimental design 
sRNAs are differentially expressed in response to environmental 
conditions and growth phase (3, 17). To maximize efficiency in identifying the 
entire UPEC sRNA repertoire using RNA-Seq, RNA was collected from the 
reference UPEC isolate UTI89 at different phases of growth and following 
exposure to different environmental stresses (Fig 5.1). Briefly, overnight cultures 
of UTI89 were subcultured into modified M9 minimal media and collected and 
immediately treated with RNAlater (Qiagen) after reaching mid-log (3 h) and 
stationary phase growth (5 h). Bacteria were also collected after reaching mid-log 
growth (3 h) and subsequent 30-min exposures to oxidative stress (1 mM methyl 
viologen; MV) or nitrosative stress (1 mM S-nitrosoglutathione; GSNO). Finally, 
RNA was isolated from UTI89 recovered from the bladders of infected mice. 
Adult female C57Bl/6 mice were infected with 107 CFU of UTI89 via transurethral 
catheterization and sacrificed 6 h or 9 d later. Bladders were collected and 
homogenized in RNAlater containing Triton X-100. Bacteria within the tissue 
homogenates were then harvested using magnetic beads coupled with anti-E. 
coli antibodies. RNA was isolated from the bacteria-enriched fraction and 
prepared for deep sequencing using an Illumina HiSeq 2000 machine. As has 
been described previously, prior to library creation each sample was treated with 
terminator exonuclease to remove unwanted tRNA and rRNA transcripts (45). 
However, with our UTI89 samples, the terminator exonucleause treatment failed 
to effectively remove rRNA and tRNA species. Even so, sufficient reads were 
	  	   	  
 
Figure 5.1 Experimental approach 
After overnight growth, UTI89 was subcultured and grown for 2.5 h before addition of stressors to appropriate samples for 
30 min. At 3 h postinoculation (5 h for stationary phase samples), total RNA was isolated from the bacteria. Alternatively, 
mice infected with 107 UTI89 were sacrificed at 6 h and 9 d after infection. Bladders were aseptically removed and 
homogenized in the presence of RNAlater before isolation of UTI89 using MACs magnetic bead separation, followed by 
isolation of total RNA. Sequencing then followed library preparation with a Qiagen sRNA kit on an Illumina HiSeq 2000 







6 h /9 d
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obtained to analyze the UTI89 RNA profile and identify sRNAs. The RNA-Seq 
experiment results are summarized in Table 5.2. The in vitro samples provided 
fair coverage of the bacterial genome, whereas the majority of reads from 
infected mouse samples were mapped to the mouse genome. Due to the nature 
of these results, the infected mouse samples were not used to identify novel 
sRNAs; however, they were used as a guide in choosing interesting candidate 
sRNAs for further study.  
 
Identification and mapping of a subset of novel UPEC sRNA 
molecules 
Candidate sRNA loci were selected from intergenic sequences by 
comparing the relative mean expression of the candidates to neighboring open 
reading frames (ORFs), as previously described (23). The selection criteria relied 
on a  >5 fold increase in maximal expression relative to local ORFs, to prevent 
unwanted identification of 5’/3’ untranslated regions (UTR). Using these 
parameters and a minimum length of 50 nucleotides (nt), 828 unique events were 
identified from the four in vitro growth conditions. Of these 828 unique events, a 
large fraction mapped to known, conserved sRNA, while 125 loci appeared to be 
specific to UTI89, which has a notably larger genome relative to K-12 E. coli 
strains. Due to the strict parameters for candidate identification in intergenic 
regions, some known UPEC sRNAs were excluded from the candidate list; 
however, they were nonetheless still detected by RNA-Seq as shown by 
expression for nearly all known sRNA presented in Table 5.3. 
	  	   	  
 
  












M9 M  +  14,321,142   2,014   14,319,128   2,014  
M9 M  -  12,049,677   1,026   12,048,651   1,026  
M9 S  +  14,179,206   1,076   14,178,130   1,076  
M9 S  -  12,927,971   1,090   12,926,881   1,090  
M9 M N +  13,144,835   3,935   13,140,900   3,935  
M9 M O +  43,893,477   6,821   43,886,659   6,821  
C57BL/6 6 h  +  84,360,161   38,654,656   45,707,533   38,654,656  
C57BL/6 9 d  +  55,069,845   28,097,437   26,974,861   28,097,437  
1 M = Mid-Log, S = Stationary, 2 N = Nitrosative Stress, O = Oxidative Stress 
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M9 M  +  14,321,142   11,124,239   3,196,903   11,124,239  
M9 M  -  12,049,677   8,924,796   3,124,881   8,924,796  
M9 S  +  14,179,206   11,105,012   3,074,194   11,105,012  
M9 S  -  12,927,971   9,948,137   2,979,834   9,948,137  
M9 M N +  13,144,835   8,423,117   4,721,718   8,423,117  
M9 M O +  43,893,477   30,602,556   13,290,921   30,602,556  
C57BL/6 6 h  +  84,360,161   297,224   84,062,937   297,224  
C57BL/6 9 d  +  55,069,845   179,764   54,890,081   179,764  
1 M = Mid-Log, S = Stationary, 2 N = Nitrosative Stress, O = Oxidative Stress 
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Table 5.3 Known sRNA in UTI89 
 












6S RNA 3233628 3233810 182 100 3.920051913 33193 
ArcZ 
(RyhA) 3570255 3570375 120 100 4.77899108 76 
CO299 1303381 1303459 78 96 None None 
CO343 1526519 1526593 74 99 4.314314911 189 
CO362 1618775 1618997 222 92 1.344564291 47 
CO465 1997273 1997350 77 100 None None 
CO614 2801040 2800961 -79 88 6.149368843 1194 
CO664 2993549 2993655 106 94 3.188661564 5 
CO719 3324977 3325198 221 97 2.616038905 22 
CsrB 3078979 3078611 -368 99 9.22E+18 99047 
CsrC 4337194 4337438 244 99 9.22E+18 15796 
CyaR 2309664 2309750 86 100 8.328235944 345 
DicF (Qin) 1393159 1393107 -52 100 None None 
DsrA 2051411 2051325 -86 100 -1.096381041 23 
FnrS 1526285 1526403 118 100 4.343792872 48 
FlmB 74237 74137 -100 100   
GadY 3931644 3931748 104 100 1.268128131 26 
GcvB 3097201 3097405 204 100 6.404945031 4370 
GlmY 2833068 2832889 -179 99 9.694163397 8497 
GlmZ 4246425 4246596 171 100 9.601925405 11932 
IsrA 1519476 1519320 -156 89 9.22E+18 1615 
IsrB 2011755 2011598 -157 99 3.889817082 49 
MgrR 1685875 1685778 -97 99 11.15379267 349 
MicA 2973601 2973672 71 100 0.548162738 543 
MicC 1533367 1533475 108 97 1.124482031 109 
MicF 2449387 2449479 92 99 -1.492496052 248 
MicM 522554 522637 83 0 9.22E+18 1066 
OhsC 
(RyfC) 2842280 2842344 64 100 1.392317423 7 
OmrA 3166626 3166539 -87 99 4.96829114 36 
OmrB 3166823 3166742 -81 100 6.299408475 68 
OxyS 4445474 4445365 -109 100 0.231325546 169 
PsrD 1191553 1191721 168 99 0.572578776 1167 
PsrN 3464980 3465167 187 98 9.22E+18 1013 
PsrO 3531060 3531233 173 100 -0.814712315 764 
RdlA 1344644 1344706 62 98 5.027320606 44 
RdlB 1344647 1344705 58 100 5.027320606 44 
RdlC 1344647 1344707 60 98 5.027320606 44 
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Table 5.3 Continued 
 












RdlD 3966762 3966817 55 98 None None 
RnpB 3494446 3494070 -376 99 9.22E+18 113633 
RprA 1805957 1806061 104 100 1.069300912 22 
RseX 2059747 2059836 89 100 None None 
RttR 1362326 1362157 -169 96 3.241084265 24041 
RybA 815714 815626 -88 99 None None 
RybB 849252 849172 -80 100 -0.466880206 8 
RydB 1800539 1800472 -67 97 0.527081585 38 
RydC 1566408 1566345 -63 98 1.267933205 6 
RyeA 1949756 1950004 248 99 6.082444766 580 
RyeB 1949974 1949854 -120 99 5.925544279 580 
RyfA 2801035 2801339 304 95 6.149368843 1194 
RyfB 2842124 2841806 -318 95 0.914995645 73 
RyfD 2878496 2878354 -142 100 6.012575607 4153 
RyhB 3843047 3842958 -89 100 None None 
RyjA 4546838 4546699 -139 100 None None 
SgrS 81033 81258 225 89 3.665164243 428 
SibB 
(RyeD) 2290698 2290833 135 96 8.804776378 508 
SibC 
(RygC) 3234497 3234637 140 96 0.688227677 4180 
SibD 
(RygD) 3423042 3422899 -143 90 9.240411725 5257 
SibE 
(RygE) 3423042 3422901 -141 97 9.240411725 5257 
SokA 3987929 3987957 28 100 None None 
SokB 3040121 3040173 52 81 0.322222793 155 
SokC 15655 15709 54 96 -1.371226942 88 
Spot 42 4336057 4336165 108 100 10.853511 15583 
SraA 472902 472846 -56 100 0.697072867 107 
SroA 79274 79182 -92 97 6.357552005 441 
SroC 660762 660600 -162 99 3.582015217 306 
SroD 1914791 1914706 -85 100 2.433178679 42 
SroE 2788198 2788107 -91 100 1.571447694 36 
SroG 3419460 3419312 -148 100 1.532799143 625 
SsrS 3233628 3233810 182 100 3.920051913 33193 
SymR 4953860 4953936 76 90 9.22E+18 1178 
Tff 194778 194913 135 100 0.945405025 3360 
TmRNA 2899681 2900043 362 100 9.22E+18 667119 





Table 5.3 Continued 
 












Tp2 129086 128926 -160 99 None None 
Tpke11 14131 14219 88 98 -0.760930839 11 
Tpke70 2657896 2657461 -435 98 -3.064993889 4 
Raghavan1 1374543 1374797 254 98 1.418789634 400 
Raghavan2 1711379 1711567 188 98 2.092649288 36 
Raghavan3 2020653 2020844 191 97 -0.401321506 4 
Raghavan4 2418310 2418547 237 99 0.427637536 60 
Raghavan5 3240457 3240602 145 93 2.789937869 41 
Raghavan6 2418310 2418547 237 99 0.427637536 60 
Raghavan8 4265417 4265560 143 99 3.486033767 297 
Raghavan9 4344127 4344197 70 97 0.044171681 124 
Raghavan 
10 4721550 4721655 105 100 -0.097610797 80 
ECS002 3594169 3594081 -88 98 1.312142418 582 
ECS005 3924577 3924638 61 100 -0.456308723 29 
ECS007 2173339 2173290 -49 100 None None 
ECS022 3909853 3909932 79 94 2.121472666 140 
ECS001 3594169 3594081 -88 98 1.312142418 582 
1 Locations are UTI89 chromosome  
2 = (-) values indicate antisense strand 
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Characterization of sRNA candidates 
Cluster analysis showed relative expression profiles for 63 candidate loci 
meeting several criteria: presence in at least 50% of the samples, a standard 
deviation of <0.5, and relative expression values as determined above compared 
to neighboring ORFs (Fig 5.2) (15). In Figure 5.2, red boxes indicate increased 
relative expression, whereas green boxes represent decreased relative 
expression of a given locus. 11 candidate sRNAs were chosen for further 
analysis as listed in Table 5.4. The candidate sRNAs were designated UPEC 
small RNA A-K. One candidate, UsrI, was found to share significant homology to 
K-12 E. coli SibB, and was thus omitted from further analysis. Candidates were 
chosen based on high relative levels of expression from multiple samples with 
preference given to candidates with detected expression in mouse-derived 
samples. Figure 5.3 shows the genomic locus and relative expression profile for 
each candidate sRNA molecule. Northern blot analysis is in progress to validate 
expression of each candidate sRNA. Possible targets of sRNA regulation were 
identified using the TargetRNA prediction program (55, 56). The data are 
compiled in Table 5.5 and indicate a large number of putative targets for each 
sRNA candidate. 
 
sRNA knockouts grow normally in vitro 
Candidate sRNA loci were chromosomally replaced with a 
chloramphenicol resistance cassette, shown in Table 5.6, using lambda Red 
recombination and the primers listed in Tables 5.7 (14). At this time, knockout  
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Figure 5.2 Identification of UPEC sRNAs  
Cluster analysis of 828 intergenic loci resulted in 63 candidate sRNA molecules 
as described in the text. These candidates exhibited >5 fold higher expression 
compared to neighboring ORFs, were present in >50% of the samples, and 
showed a standard deviation below 0.5. 21 of 63 candidates in this analysis were 
recognized as previously annotated small RNA. Several sRNAs marked in bold 
were added to our queue for further characterization.  
  





5. C57BL/6 6 h Infection
6. C57BL/6 9 d Infection
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Figure 5.2 Continued  
Cluster analysis of 828 intergenic loci resulted in 63 candidate sRNA molecules 
as described above.  





5. C57BL/6 6 h Infection
6. C57BL/6 9 d Infection


















usrA 2370149 2370532 + yohG/yohI Yes 
usrB 4554676 4554744 +/-  yjcH/acs Yes 
usrC 4211357 4211426 - C4323/ilvG Yes 
usrD 3493994 3494397 +/- tdcR/yhaD  
usrE 2172783 2173287 + C2233/C2234  
usrF 722460 722749 - C0716/sdhC  
usrG 1071549 1071748 + ycdB/phoH Yes 
usrH2 1402995 1403179 + C1479/C1480  
usrI 
(sibB) 
2291019 2291168 + yegL/mdtA  
usrJ 2290694 2290838 +/-  yegL/mdtA Yes 
usrK2 3132555 3132694 + C3210/C3212  
NT = not tested; (+) = sense strand; (-) = antisense strand;  
2 = Absent from MG1655 
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Figure 5.3 (usrA-C) Genomic loci for each candidate sRNA  
The genetic location of each candidate is shown with neighboring 
genes, predicted promoters, and relative intergenic expression levels. 
 
	  	   	  
    
121











Figure 5.3 (usrD-F) Genomic loci for each candidate sRNA  
The genetic location of each candidate is shown with neighboring 
genes, predicted promoters, and relative intergenic expression levels. 
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Figure 5.3 (usrG,H) Genomic loci for each candidate sRNA  
The genetic location of each candidate is shown with neighboring 
genes, predicted promoters, and relative intergenic expression levels. 
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Figure 5.3 (usrJ,K) Genomic loci for each candidate sRNA  
The genetic location of each candidate is shown with neighboring 
genes, predicted promoters, and relative intergenic expression levels. 
	  	   	  

















Table 5.5 Target RNA predictions 
 







Value Score Annotation 
usrA + phoH Yes 0.0062
5011 
-63 PhoB-dependent, ATP-
binding pho regulon 
component 
 - yjfL Yes 0.0022
482 
-65 hypothetical protein 
 - blr Yes 0.0047
5229 
-61 beta-lactam resistance 
protein 
 - yniB Yes 0.0057
2919 
-60 hypothetical protein 
       
usrB + b0725 No 1.40E-
11 
-168 hypothetical protein 
 + b3004 No 1.87E-
10 
-154 hypothetical protein 
 + phnE Yes 6.53E-
05 
-85 membrane channel 
protein component of 
Pn transporter 
 + phoR Yes 0.0031
7286 
-64 positive and negative 
sensor protein for pho 
regulon 






 + yjeQ Yes 0.0079
8129 
-59 hypothetical protein 
 - b0725 No 5.60E-
06 
-92 hypothetical protein 
 - ybiO Yes 2.23E-
05 
-85 putative transport 
protein 
 - yicM Yes 7.31E-
05 
-79 putative tranport 
protein (MFS family) 




 - hokB Yes 0.0083
5072 
-55 small toxic membrane 
polypeptide 
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Table 5.5 Continued 
 







Value Score Annotation 
usrC + dnaT Yes 0.0008
90563 
-71 DNA biosynthesis; 
primosomal protein  
 + yojI Yes 0.0012
8814 
-69 putative ATP-binding 
component of a 
transport system 








 + yjgH No 0.0081
3573 
-59 hypothetical protein 





 - hofB Yes 3.21E-
05 
-89 putative integral 
membrane protein 
involved in biogenesis 
of fimbriae (type IV 
pilin), protein transport, 
DNA uptake 
 - fumC Yes 3.21E-
05 
-89 fumarase C (fumarate 
hydratase Class II) 








common antigen (ECA) 
 - ybcW No 0.0007
40466 
-72 DLP12 prophage 







 - hyaE Yes 0.0012
8814 
-69 processing of HyaA 
and HyaB proteins 





 - ydhD Yes 0.0015
4917 
-68 hypothetical protein 
	  	   	  
130	  
Table 5.5 Continued 
 







Value Score Annotation 






 - uidB Yes 0.0018
6305 
-67 glucuronide permease 
 - rihA Yes 0.0022
4044 
-66 pyrimidine specific 
nucleoside hydrolase 
 - yfdI No 0.0022
4044 
-66 CPS-53 (KpLE1) 
prophage; putative 
ligase 
 - yhdP Yes 0.0022
4044 
-66 hypothetical protein 
 - yqjH Yes 0.0026
9419 
-65 hypothetical protein 
 - glcF No 0.0026
9419 
-65 glycolate oxidase iron-
sulfur subunit 
 - yebE Yes 0.0032
3968 
-64 hypothetical protein 
 - yihE Yes 0.0032
3968 
-64 hypothetical protein 
 - yafP Yes 0.0046
8352 
-62 hypothetical protein 
 - yhiU Yes 0.0046
8352 
-62 multidrug resistance 
protein (lipoprotein) 
 - pepA Yes 0.0056
3065 
-61 aminopeptidase A, a 
cyteinylglycinase 
 - glnD Yes 0.0067
6866 
-60 protein PII; 
uridylyltransferase acts 
on regulator of glnA 
 - iciA Yes 0.0067
6866 
-60 inhibitor of replication 
initiation; 
transcriptional 
regulator of dnaA and 
argK (LysR family) 
 - yghW Yes 0.0067
6866 
-60 hypothetical protein 
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Table 5.5 Continued 
 







Value Score Annotation 
usrD + yfdM Yes 0.0036
8172 
-77 CPS-53 (KpLE1) 
prophage; putative 
transferase 
 + ymfS No 0.0042
84 
-76 e14 prophag 
 + nagE Yes 0.0067
4692 
-73 PTS family enzyme IIC 
(N-terminal); enzyme 




 + yjbL No 0.0091
2949 
-71 hypothetical protein 
 - cysG Yes 0.0019
7729 





 - rfaC Yes 0.0031
1789 
-78 ADP-heptose; LPS 
heptosyl transferase I 
 - ydbH Yes 0.0042
2324 
-76 hypothetical protein 
 - ais Yes 0.0049
1482 
-75 protein induced by 
aluminum 
 - modB Yes 0.0077
4335 
-72 molybdate transport 
permease protein 
 - yghS Yes 0.0077
4335 
-72 hypothetical protein 
       
usrE + galK Yes 0.0005
15225 
-92 galactokinase 
 + yafM Yes 0.0022
7162 
-82 hypothetical protein 
 + ppk Yes 0.0026
3468 
-81 polyphosphate kinase 
 + ybaS Yes 0.0030
5569 
-80 putative glutaminase 
 + yfaL Yes 0.0074
2996 
-74 hypothetical protein 
 + era Yes 0.0074
2996 
-74 GTP-binding protein 
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Value Score Annotation 
 - ygaQ No 0.0005
86795 
-91 hypothetical protein 









 - yggV Yes 0.0054
428 
-76 hypothetical protein 





 - wzxC Yes 0.0098
4235 
-72 probable export protein 
       
usrF + ymfC Yes 0.0063
3458 
-71 hypothetical protein 
 + b1995 Yes 0.0074
0728 
-70 CP4-44 prophage; 
putative hemine 
receptor 





       
usrG + ygeA Yes 0.0017
7428 
-76 putative aspartate 
racemase 
 + ycbL Yes 0.0055
5936 
-69 hypothetical protein 
 + fucU Yes 0.0065
4313 
-68 conserved protein of 
fucose operon 
 + rihB Yes 0.0090
612 
-66 pyrimidine specific 
nucleoside hydrolase 
 - phoH Yes 4.55E-
15 
-239 PhoB-dependent, ATP-
binding pho regulon 
component 
       
usrH + ygeY Yes 0.0022
2102 
-74 putative deacetylase 
 + yciA Yes 0.0059
5914 
-68 hypothetical protein 
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Value Score Annotation 
 + cysU Yes 0.0070
2305 
-67 sulfate, thiosulfate 
transport system 
permease T protein 
 + ydaV No 0.0082
7611 
-66 Rac prophage; putative 
DNA replication protein 
 - yfcE Yes 0.0010
4863 
-77 hypothetical protein 




-75 hemolysin E 
 - yebW Yes 0.0017
3595 
-74 hypothetical protein 
 - ynjC Yes 0.0040
1929 




 - ygaV Yes 0.0040
1929 
-69 hypothetical protein 




 - yghS Yes 0.0078
5957 
-65 hypothetical protein 
 - yjjI Yes 0.0092
9196 
-64 hypothetical protein 
       
usrJ + chpR Yes 0.0005
66207 
-78 part of proteic killer 
gene system, 
suppressor of inhibitory 
function of ChpA 
 + erfK Yes 0.0011
3482 
-74 hypothetical protein 
 + yehI Yes 0.0013
502 
-73 putative regulator 
 + ygfM Yes 0.0013
502 
-73 hypothetical protein 
 + tolB Yes 0.0032
1797 
-68 periplasmic protein 
involved in the tonb-
independent uptake of 
group A colicins 
 + ymgD Yes 0.0032
1797 
-68 hypothetical protein 
 + yecG Yes 0.0038
2796 
-67 hypothetical protein 
 + cydA Yes 0.0045
5332 
-66 cytochrome d terminal 
oxidase, polypeptide 
subunit I 
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Value Score Annotation 











 + yfbP No 0.0054
1575 
-65 hypothetical protein 
 + ybjP Yes 0.0076
5959 
-63 hypothetical protein 
 + yieH No 0.0076
5959 
-63 putative enzyme with a 
phophatase-like 
domain 
 + argH Yes 0.0076
5959 
-63 argininosuccinate lyase 
 + hflC Yes 0.0076
5959 
-63 protease specific for 
phage lambda cII 
repressor 
 + ybeQ Yes 0.0091
0767 
-62 hypothetical protein 







 - tonB Yes 0.0038
2796 
-67 energy transducer; 
uptake of iron, 
cyanocobalimin; 
sensitivity to phages, 
colicins 




 - pspF Yes 0.0054
1575 
-65 psp operon 
transcriptional activator 
 - cyoE Yes 0.0064
41 




 - rhtB Yes 0.0064
41 
-64 amino acid exporter 
(homoserine, HSL) 
 - kefA Yes 0.0076
5959 
-63 component of the 
MscS mechano-
sensitive channel 
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Table 5.5 Continued 
 







Value Score Annotation 
 - recT No 0.0076
5959 
-63 Rac prophage; 
recombinase, DNA 
renaturation 
 - ygiA Yes 0.0076
5959 
-63 hypothetical protein 
 - yhjT Yes 0.0076
5959 
-63 hypothetical protein 
       
usrK + glxR Yes 0.0014
0146 
-73 tartronic semialdehyde 
reductase 





 + fldA Yes 0.0039
6099 
-67 flavodoxin 1 
 + srlR Yes 0.0039
6099 
-67 regulator for gut (srl), 
glucitol operon 




 + elaC Yes 0.0066
5435 
-64 hypothetical protein 
 + yfdN Yes 0.0066
5435 




 - fldA Yes 0.0007
55175 
-78 flavodoxin 1 




enzyme II for 
cellobiose, arbutin, and 
salicin 





 - hslO Yes 0.0034
8885 
-69 Hsp33; redox regulated 
chaperone 




-67 hypothetical GST-like 
protein 
 - ycbW Yes 0.0096
5654 
-63 hypothetical protein 








Table 5.6 Strains and plasmids used in this study 
 
Strains Description Reference 
E. coli   
UTI89 UPEC reference strain and cystitis isolate (5, 11, 32) 
DH5α Cloning strain  




UTI89∆usrA UTI89 usrA::cat This work 
UTI89∆usrB UTI89 usrB::cat This work 
UTI89∆usrC UTI89 usrC::cat This work 
UTI89∆usrG UTI89 usrG::cat This work 
UTI89∆usrJ UTI89 usrJ::cat This work 
   
Plasmids   
pKM208 Encodes lambda Red recombinase for 
creation of knockout strains 
(33) 
pKD3 Plasmid containing chloramphenicol 
resistance cassette for use in lambda-Red 
recombination 
(14) 
pRR48 IPTG inducible overexpression of protein 
coding sequence Apr 
(52) 
pRRK1 Modified pRR48 lacking Shine-Delgarno 
sequence for overexpression of sRNA Apr 
R. Kulesus 
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Table 5.7 Oligonucleotides employed during the study 
 
 































a F, forward Primer; R, reverse Primer; KO, knockout primer; Conf, confirmation 
primer 
b Universal Primer sequence underlined 
















Figure 5.4 Growth and biofilm formation of candidate knockouts 
Growth of UTI89∆usrA/B/C/G/J in (A) LB, (B), modified M9 minimal media, (C) 
M9 containing 0.3 mM MV, and (D) M9 containing 1.0 mM GSNO. Each 
experiment (A-D) is representative data from one of three experiments performed 
in quadruplicate. Error bars were negligible and thus omitted. In vitro biofilm 
formation assays in modified M9 minimal media at (E) 30°C and (F) 37°C. Data 
represents the mean ±SE of at least three independent experiments performed in 
quadruplicate. P values were determined by Student’s t test; *P<0.05, **P<0.01, 
***P<0.001, versus the wild type control. 






































































































































strains of the usrA, B, C, G, and J regions have been successfully generated. 
The sRNA knockouts exhibited no deviations from wild type in Luria Bertani (LB) 
broth or modified M9 minimal media (Fig 5.4A-B). Knockouts challenged with 1 
mM MV or 1 mM GSNO also exhibited no alterations in growth (Fig 5.4C-D). 
 
sRNA knockouts contribute to biofilm formation 
Despite normal growth under stress conditions, UTI89∆usrA, B, G, and J 
exhibited mild defects when challenged to form biofilms in vitro in plastic 
microtiter plates. All of the defects were observed at 37°C, with no changes 
observed at 30°C in modified M9 minimal media (Fig 5.4E-F). Defects in biofilm 
formation in these assays is not attributable to the presence of the 
chloramphenicol resistance cassette used to construct the mutants, as many 
strains carrying the same cassette in this and other assays behave like the wild 
type strain with respect to biofilm formation. Examination of UTI89∆usrA and 
UTI89∆usrB indicated normal levels of yeast agglutination, indicating normal 
formation of type I pili.  
 
UsrB contributes to virulence in a mouse model of UTI  
RNA-Seq analysis from infected mouse samples was utilized as a tool for 
selection of candidate sRNA molecules, and thus each knockout strain was 
assessed for virulence potential using a murine model of UTI. Mice were infected 
with 107 CFU of wild type or mutant UTI89 via transurethral catheterization and 
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bacterial titers within the bladder were determined at 6 h and 9 d postinoculation. 
Interestingly, at 6 h postinfection, UTI89∆usrB consistently showed ~4.5 fold 
greater titers than wild type (Fig 5.5A). UTI89 lacking usrA, C, or G behaved like 
the wild type strain 6 h post infection. By 9 d postinfection, titers UTI89∆usrA and 
UTI89∆usrB were not significantly altered from wild type UTI89 (Fig 5.5B). In 
competitive infection assays, in which UTI89∆usrA or UTI89∆usrB are infected 
with an equal number of wild type UTI89, no differences between the wild type 
and mutant strains were observed at a 3 d time point (Fig 5.5C). In total, these 
data indicate that these sRNAs so far examined have at best only minimal impact 




An explosion of deep sequencing studies has flooded the field of bacterial 
RNA in recent years, with many focused on the identification of previously elusive 
sRNA molecules. The data in Table 5.1 clearly demonstrate the recent accretion 
of sRNA sequencing efforts, which have brought many novel sRNAs to the 
forefront. Since pathogenic strains often exhibit more robust stress response, 
iron scavenging, and antibiotic resistance characteristics than traditional 
laboratory strains of E. coli, we concentrated on sRNA molecules which could be 
identified during these processes, namely during growth in redox stressors and 
during murine UTI. Hence we utilized UPEC as a model organism to study the 
infection of the sterile niche of the bladder. 
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Figure 5.5 UsrB represses bladder colonization  
Adult female CBA/J mice were inoculated via transurethral catheterization with 
107 CFU of UTI89, UTI89∆usrA, UTI89∆usrB, UTI89∆usrC, or UTI89∆usrG. (A-C) 
Bacterial titers were determined from infected bladders 6 h and 9 d post-
inoculation, in agreement with time points from RNA-Seq. (C) For competitive 
assays, mice were infected with equal numbers of the wild type and mutant 
strains (107 CFU total) and bladder titers were calculated 3 d postinfection. Bars 
denote median values for each group. Graph A + C depict cumulative results 
from two independent assays (n = 11 mice per group). Panels B + D are in 
progress and indicate data from one experiment. *P<0.05, as determined using 
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RNA-Seq and subsequent bioinformatics analysis provided us with a 
putative list of sRNA loci. Interestingly, these results suggested a slightly 
enriched sRNA population in UTI89 specific genomic sequences (135%) 
compared to the K-12 strain, MG1655. A higher frequency of sRNAs in UPEC-
specific sequences suggests that pathogens may acquire or even evolve more 
sRNAs to refine stress response and virulence regulatory cascades. UPEC 
strains also exhibit increased resistance to stress challenge as compared to K-12 
strains, which would likely require more intricate regulatory capacity (unpublished 
data). RNA-Seq experiments provide a wealth of sequence information, but still 
likely fail to identify all possible sRNA species due to overwhelming quantities of 
certain prevalent species. Deeper sequencing would thus be required to 
unequivocally prove that pathogens have an inflated sRNA repertoire compared 
to nonpathogenic strains.  
828 candidate sRNA loci were revealed in intergenic regions of UTI89 
through RNA-Seq. Of these candidate loci, 11 were chosen for further study due 
to their relative levels of expression compared to neighboring ORFs and across 
multiple samples. Six candidates were initially knocked out using lambda Red 
recombination. Chromosomal knockouts of candidate loci exhibited no change in 
growth in vitro in rich media, minimal media, or after challenge with redox 
stressors. Biofilm formation was, however attenuated in UTI89∆usrA, B, G, and 
J, as quantified by in vitro biofilm formation assays in plastic microtiter plates. 
Biofilm formation in vitro has been shown to correlate with pathogen virulence in 
vivo (51), and thus acts as a proxy for identification of factors that may affect the 
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virulence potential of a given UPEC strain. Intriguingly, deletion of the sRNA 
UsrB was found to promote colonization of the murine bladder at 6 h 
postinfection, suggesting that this sRNA is a negative regulator of bacterial 
fitness and/or virulence within the acute phase of a UTI.  
In order to glean more information of putative downstream targets of 
sRNAs, candidate regions were run through the sRNA target prediction program, 
TargetRNA, against the genome of a MG1655 K-12 E. coli (Table 6) (55, 56). 
TargetRNA predicts mRNA targets of sRNAs by searching for homology over a 
defined region of the mRNA. The standard search narrows this window to the 50 
nt surrounding the ribosome binding site. The caveat to using TargetRNA to 
predict mRNA targets in UTI89 is the reliance on the K-12 genome as the query, 
since the UTI89 genome sequence is currently not available with this analysis. 
As it stands, all identified putative sRNA targets are present in MG1655, which 
has a reduced genome compared to the pathogens and fails to express many of 
the known UTI89 virulence factors. Nonetheless, the list of putative targets 
provides insight into the possible cellular focus of each sRNA. One possible 
explanation for UsrB effects on virulence could be through direct repression of 
the PhoR expression. PhoR has been implicated in virulence factor expression in 
Edwardsiella tarda in response to changes in inorganic phosphate levels, which 
are typically depleted in host niches in response to infection (8). It is possible that 
UsrB may repress PhoR in UTI89, resulting in accelerated virulence factor 
production by this pathogen early on during UTI, while later during the infection 
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process this effect may be countered by host-mediated depletion of inorganic 
phosphate.  
In conclusion, this study presents the putative sRNA repertoire of a 
reference UPEC isolate, and begins to probe the potential roles of several novel 
UPEC sRNAs in UTI pathogenesis. These early results indicate that UPEC 
isolates likely encode an expanded set of sRNAs in comparison with non-
pathogenic K-12 strains, and suggest roles for both conserved, and possibly 
UPEC-specific, sRNA molecules as regulators of bacterial virulence and fitness 
within the urinary tract. The example of UTI89∆usrB demonstrates that sRNA 
molecules may also be utilized to reign in overzealous virulence effectors during 
the course of infection, a previously underappreciated function of sRNAs. 
Additional work is required to validate the expression and functionality of the 
putative sRNAs identified here, but the data already in hand open up exciting 
new avenues by which we can better understand and manipulate the virulence 
potential of UPEC and related pathogens.  
 
Materials and Methods 
RNA isolation  
RNA isolation was performed using the Norgen Total RNA Isolation Kit 
(Norgen Biotek) according to the manufacturers protocol with minor alterations. 
Briefly, 500 µl of cultured bacteria are mixed with 1 ml of RNA Later (Ambion) 
and incubated for 10 min at RT. Bacterial cells are then pelleted at 10000 X g for 
10 min in a table top centrifuge followed by addition of RNase-free Tris-EDTA 
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Buffer (Fluka Analytical) containing 15 mg/ml lysozyme (Sigma-Aldrich) and 15 
mg/ml proteinase K (Sigma-Aldrich) for 30 min at RT to prepare bacteria for lysis. 
300 µl of Norgen lysis solution is then added to samples and vortexed for 15 s, 
followed by addition of 200 µl of 4°C ethanol and 15 s of vortexing. Samples are 
then added to the Norgen RNA isolation column and centrifuged at max speed in 
a tabletop centrifuge for 1 min at RT. After three washes in 400 µl of Norgen 
Wash Buffer, two additional minutes of centrifugation ensured removal of ethanol 
before elution with 50 µl of H2O (2 min 200 x g followed by 1 min max speed at 
RT).  
Total RNA isolated from UPEC strains was then treated with Turbo DNase 
(Ambion) extensively to remove DNA contamination. Samples were treated with 
10-14 U Turbo DNase in a reaction volume of 200 µl for 1 h at 37°C. In certain 
cases a second DNase reaction was performed after using a Norgen RNA Clean-
Up and Concentrate Kit (Norgen Biotek). Following DNase treatment, RNA was 
mixed with 200 µl acid-phenol-chloroform pH 6.7 and centrifuged for 5 min at 
max speed. Aqueous phase was transferred to a new 1.5 ml tube and 180-200 µl 
of chloroform was added, followed by centrifugation for 5 in at max speed at RT. 
Aqueous phase was again transferred to a new tube and precipitated with 
ethanol using 0.1 volume 5 M NH4Ac, linear acrylamide as a carrier, and 2.5 
volumes ice-cold ethanol at -80°C overnight. RNA was then recovered by 
centrifugation for 30 min at 4°C before drying for 5 min, and resuspension in ~25 
µl of H2O. The Turbo DNase treatment was then repeated followed by acid 
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phenol chloroform and ethanol precipitation. Sample concentrations were 
determined by Nanodrop analysis (Thermo Scientific).  
 
RNA-Seq 
 Total RNA depleted of DNA from all samples was treated with Terminator 
5’-Phosphate-Dependent Exonuclease (EpiCentre Biotechnologies) in 1X 
Terminator Reaction Buffer, RiboGuard RNase Inhibitor, and 1 U enzyme per 2.5 
µg total RNA, for 30 min at 37°C to remove rRNA and tRNA as previously 
described (45). Samples were then acid-phenol-chloroform- and ethanol-
precipitated as described above. All samples were then provided to the 
Huntsman Cancer Institute Sequencing Core for library creation and sequencing 




The sequencing reads were processed as follows: homopolymeric and low 
quality (Illumina pipeline quality scores less than 15 in 15 or more positions) 
sequences were removed; exact duplicate reads were compressed in to single 
fasta records, noting the number of occurrences of the duplicate sequences.  
Sequences from in vitro and in vivo samples were aligned to the UTI89 
chromosome and plasmid, GenBank IDs 91209055 and 91206245 respectively. 
Additionally the in vivo samples were aligned to the Mus musculus genome 
(UCSC build: mm9). All alignments were performed using the bowtie aligner 
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(PMC2690996). RNA expression of a region (e.g. ORF, sRNA, etc.) was 
calculated as the number of reads which overlap one or more positions in the 
region per thousand reads obtained per sample and normalized to the length of 
the region: (region reads)/(kiloreads * kilobase). Intergenic expression was also 
considered relative to the adjacent 3' and 5' OFRs and expressed as the log2 
ratio of the intergenic region vs. the expression of the 3' of 5' ORF, whichever is 
greater. Putative rho independent terminator sites were identified using 
TransTermHP (PMC1852404), and σ70 binding sites were calculated using an E. 
coli specific position weight matrix and custom software written in python (KF 
Fischer pers. comm.). These data were exposed to the internet using Distributed 
Annotation System and displayed using a custom genome browser, developed 
using Dalliance (http://www.biodalliance.org). 
 
Growth conditions 
The prototypic UPEC isolate UTI89 and its derivatives were cultured from 
freezer stocks in LB broth or modified M9 minimal media (6 g/l Na2HPO4, 3 g/l 
KH2PO4, 1 g/l NH4Cl, 0.5 g/l NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 
0.0025% nicotinic acid, 0.2% casein amino acids, and 16.5 µg/ml thiamine in 
H2O) (Sigma-Aldrich) as previously described (63). Bacteria were grown at 37°C 
overnight in loosely capped 20-by-150-mm borosilicate glass tubes at a 30° 
angle with shaking at 225 rpm. Overnight cultures were diluted 1:100 into 100-
well honeycomb plates and assayed for growth using a Bioscreen C instrument 
(Growth Curves USA). Growth was assessed in LB broth, M9 media, M9 media ± 
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1 mM GSNO (Sigma-Aldrich), or M9 media ± 1 mM methyl viologen (MV; Sigma-
Aldrich). As previously described, antibiotics were added only for maintenance of 
plasmids in overnight cultures and were not included during growth assays 
(Sigma-Aldrich). Strains utilized in this study are listed in Table 7.  
 
Biofilm assays 
Microtiter plate-based biofilm assays were performed as described 
previously (24). Briefly, overnight cultures of UTI89 were grown shaking at 225 
rpm at 37°C in LB broth before subculture 1:100 into M9 minimal media. 100 µl of 
sample was then plated in quadruplicate on 96-well pinchbar flat-bottomed 
polystyrene microtiter plates (NUNC). Samples were surrounded by a row of H2O 
to minimize evaporation. After 48 h at 30 or 37°C, planktonic bacteria were 
removed by washing with tap water two times. 150 µl of 0.1% crystal violet 
solution was added for 10 min. The wells were then rinsed twice with H20 and air-
dried. To solubilize the dye, 200 µl of dimethyl sulfoxide (Sigma-Aldrich) was then 
added to each well and vigorously shaken for 15 min on an orbital shaker. The 
absorbance of each well was then read by measuring A562 using a Synergy HT 
multi-detection microplate reader (BioTek Instruments, Inc.). 
 
Mouse infections 
Seven- to 8-week-old female C57BL/6 mice (Jackson Laboratory) were 
anesthetized by isoflurane inhalation. Mice were then slowly inoculated by 
transurethral catheterization with 50 µl of bacteria (~107 CFU from 24 h static M9 
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minimal media cultures) resuspended in PBS as described previously (24). Mice 
were infected for use in multiple downstream applications, including RNA 
isolation for RNA-Seq and knockout characterization. Infected mice for RNA-Seq 
were sacrificed at 6 h or 9 d post infection. The bladders were aseptically 
removed and pooled in RNA Later (Ambion) containing 0.025% Triton X-100 and 
homogenized to lyse host cells. Pooled samples were centrifuged at 10,000 X g 
for 3 min in a tabletop centrifuge at RT. After resuspension in RNA Later, 
samples were filtered through 100 micron nylon mesh (Sefar) to remove large 
particulates from the bladder. Samples were then incubated with rabbit anti-E. 
coli antibody (Meridian Life Science, Inc) for 5-10 min at 4°C at a dilution of 1:50. 
Cells were washed with 1 mL RNA Later and centrifuged for 3 min at 10000 X g. 
Samples were resuspended in 80 µl of RNA Later and added to 20 µl of α-Rb 
IgG antbody-coated MACs Beads (Miltenyi Biotec) for 15 min at 4°C. The cells 
were then washed by adding 1 ml RNA Later followed by centrifugation at 600 X 
g for 10 min at RT followed by complete removal of supernatant. Samples were 
resuspended in RNA Later and passed through a MACs beads magnetic column 
according to manufacturers instructions. All washes were done using RNA Later 
to minimize changes to RNA profile. Bacteria were eluted from the column in 1 ml 
of RNA Later and RNA was immediately isolated using the Norgen Total RNA 
Isolation kit (Norgen Biotek).  
Candidate sRNA knockouts were characterized in the murine model of 
UTI for contributions to pathogenesis. Seven- to 8-week- old female C57BL/6 
mice were infected with 107 UTI89 or knockout strain for 6 h or 9 d as described 
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above. For competition experiments, equal titers of wild type and a single 
knockout strain were co-infected as described into mouse bladders for 3 d before 
sacrifice. For both experimental approaches mice were sacrificed and bladders 
aseptically removed, weighed, and homogenized in 0.025% Triton X-100 as 
previously described (24). Samples were serially diluted and plated to determine 
bacterial titers per gram of bladder tissue. Eleven mice total, from two 
independent experiments, were used for each group.  
 
Statistical analysis 
P values were determined by Student’s t test or Mann-Whitney U tests 
performed using Prism 5.01 software (GraphPad Software). Values of less than 
0.05 were deemed significant. 
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Abstract 
In Escherichia coli the enzymes MiaA and MiaB modify adenosine-37 of 
UNN-recognizing tRNAs. The first enzyme in this pathway, MiaA, has been 
extensively linked to translational efficiency and reading frame maintenance, 
while the function of the second enzyme, MiaB, remains elusive. In this study, we 
directly compare MiaA and MiaB for their contribution to stress resistance, 
behavior in the form of motility and biofilm assays, and virulence in 
uropathogenic E. coli. Interestingly, MiaA and MiaB did not contribute equally to 
stress response. MiaA was shown to contribute to growth in osmotic, oxidative, 
and nitrosative stress in the pathogen, whereas MiaB did not affect growth. We 
observed a dosage effect with MiaA, where both limiting and excess expression 
of MiaA resulted in decreased growth in response to stressors. We observed a 
corresponding decrease in MiaA protein expression after stress treatment. In 
regards to behavior, both MiaA and MiaB were shown to differentially regulate 
biofilm formation, however only MiaA regulates motility. A murine model of 
urinary tract infection indicated that MiaA contributes to virulence, whereas MiaB 
had no effect on pathogenesis. Infection of mouse urinary tracts with a miaA 
knockout resulted in attenuated infection at 1, 3, and 9 days, and a decreased 
reservoir population at day 9 of infection. Of note, the pore-forming toxin α-
hemolysin was not expressed in a miaA knockout, despite increased levels of 
transcript. Therefore, differential regulation of A-37 specifically by MiaA results in 
drastic deviations to uropathogenic E. coli stress response, behavior, and 
virulence.  
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Author Summary 
The bacterial ribosome translates a messenger RNA into a functional 
protein with the help of another form of RNA, known as transfer RNA. To 
accurately achieve high fidelity protein translation, transfer RNA molecules are 
often modified with additional chemical groups to increase specificity within the 
ribosome. Previous studies have elicited roles for tRNA molecules in a wide 
range of bacterial behaviors, including translation efficiency, stress response, 
and virulence, among others. The MiaA enzyme imparts a modification that is 
linked to translational fidelity and, subsequently, stress response and virulence. It 
is hypothesized that decreased levels of MiaA allows for alternate protein folding 
motifs and possibly functions by incorporation of errors in the protein sequence. 
In our study, we find that uropathogenic E. coli down-regulates MiaA in response 
to stressors, consistent with the above model. Additionally, MiaA activity is 
implicated in bacterial behavior, toxin formation, and virulence in a mouse model 
of infection. Our study shows further evidence that transfer RNA modification is 
important as a global switch to modulation bacterial behaviors and stress 




The ribosome is among the most important, indispensible molecular 
machines in the cell. The charge of the ribosome is to turn stored genetic 
information into a physical output in the form of functional proteins. Ribosomal 
proteins and catalytic RNA molecules coalesce into an elegant structure, which 
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binds to and translates messenger RNA (mRNA) (for review see (15, 34, 36, 
45)). Along with ribonucleoproteins and ribosomal RNA, a molecular translator, or 
transfer RNA (tRNA), is required to bridge the gap between mRNA and protein. A 
unique portion of the tRNA known as the anticodon sequence recognizes a 
codon in frame on the mRNA presented in the A-site of the ribosome. Once a 
tRNA molecule correctly identifies the anticodon in the A-site of the ribosome, the 
appropriate amino acid is added to the growing peptide chain in the P-site. The 
tRNA then exits the ribosomal E-site to complete its reaction. Multiple levels of 
regulation further complicate this simplified model of translation. In particular, 
extensive modification of both rRNA and tRNA molecules alters and often 
improves the efficiency of translation by the ribosome. tRNA molecules, in 
particular, may be modified with more than 75 moieties, including methyl, 
hydroxyl, and prenyl groups (38). The fully modified, or mature, tRNA properly fits 
into the ribosome and interacts correctly with the mRNA, contributing to 
maintenance of both reading frame and translational fidelity (5).  
 tRNA modification is now known to affect the regulation of cellular 
physiology and myriad other processes in bacteria through mammals. Although 
classically thought to primarily affect translational fidelity and efficiency, recent 
studies have implicated tRNA modification as more of a global regulator of 
cellular processes. In addition to functioning in translational fidelity, Chan et al. 
recently observed dynamic control of tRNA modification marks in response to 
cellular stresses, including oxidative stress (9). Similarly, studies in 
Streptomyeces pyogenes have implicated tRNA modification by GidA/MnmE as 
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necessary for virulence in a murine subcutaneous ulcer model (11). Another 
example of stress response and virulence regulation by tRNA modification can 
be observed with the pseudouridine synthesis gene TruA, which is required for 
type III secretory genes in Pseudomonas aeruginosa (1). Finally, deletion of 
enzymes required for addition of specific tRNA modifications have been utilized 
as attenuated vaccines in bacterial pathogens such as Streptomyeces pyogenes, 
further necessitating the need for more study in alternate organisms (11). 
Consequently, tRNA modifications play diverse roles in regulation of stress 
response and virulence in a wide range of bacterial pathogens.  
One of the most commonly modified tRNA residues in bacteria is 
adenosine-37 (A-37), which lies adjacent to the anticodon loop (27). A-37 of UNN 
(U=uridine, N=any nucleotide)-recognizing tRNA, in its final form, is both 
prenylated and methylthiolated (38). The miaA gene of Escherichia coli encodes 
a tRNA prenyltransferase responsible for catalyzing the addition of a prenyl 
group onto the N6-nitrogen of A-37 to create i6A-37 tRNA (8) (Fig. 6.1A). The 
modified i6A-37 residue is then further methylthiolated by the radical-S-
adenosylmethionine enzyme MiaB to create ms2i6A-37 (39-41). The ms2i6A-37 
modification is then required to correctly identify target codons (UNN) in the 
ribosomal A-site and, ultimately, functions in reading frame maintenance and 
translational fidelity (46). The ms2i6A-37 modification is highly conserved in 
prokaryotes through eukaryotes, yet the enzymes that mediate this modification 
have diverged through evolutionary time. However, in prokaryotes MiaA and  
 
 

















Figure 6.1 UTI89∆miaA exhibits wild type growth despite severely altered 
metabolism  
 
(A) Model of MiaA and MiaB action modified from Leung et al. (32). (B- D) 
Growth of miaA and miaB knockouts in LB broth, M9 minimal media, and LB-
MES (pH 5.0) broth. Graphs in B-D show representative data of the mean of 4 
replicates from at least 3 independent experiments. Error bars were negligible 
and omitted for clarity. (E) Metabolomics of common bacterial metabolites as 
determined by GC/MS. Bar graph shows list of significantly altered metabolites in 
UTI89∆miaA compared to UTI89 with a list of unchanged metabolites to the right 
of the figure. Data are presented as the mean of six independent replicates ±SD, 
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Figure 6.1 Continued 
 
(A) Model of MiaA and MiaB action modified from Leung et al. (32). (B- D) 
Growth of miaA and miaB knockouts in LB broth, M9 minimal media, and LB-
MES (pH 5.0) broth. Graphs in B-D show representative data of the mean of 4 
replicates from at least 3 independent experiments. Error bars were negligible 
and omitted for clarity. (E) Metabolomics of common bacterial metabolites as 
determined by GC/MS. Bar graph shows list of significantly altered metabolites in 
UTI89∆miaA compared to UTI89 with a list of unchanged metabolites to the right 
of the figure. Data are presented as the mean of six independent replicates ±SD, 


































































































































































MiaB have relatively high conservation levels across species, and the enzymes 
appear to function similarly in all tested microorganisms (32). 
MiaA consists of two domains, a large core domain and a small helix 
insertion domain, separated by a large basic fissure (43). The anticodon of the 
tRNA binds to the basic rift of MiaA, causing a rearrangement in the tRNA 
anticodon loop structure, juxtapositioning the A-37 residue for modification (31). 
Mutations in the miaA locus result in inefficient modification of the A-37 residue, 
leading to hypomodified tRNAs having altered A-site ribosomal interactions and 
increased peptidyl-tRNA slippage (47). In K-12 E. coli strains, disruption of MiaA-
dependent translational regulation appears to influence tryptophan operon 
attenuation, aerobiosis, phenylalanine utilization, and spectinomycin resistance 
(37). Furthermore, miaA mutants show increased spontaneous mutagenesis, a 
process, which is mimicked by iron limitation (13). In addition, expression of miaA 
is increased in response to the mismatch mutagen 2-aminopurine, consistent 
with a role for MiaA in preventing DNA mutagenesis and contributing to stress 
response (12). It has thus been hypothesized that regulation of miaA expression 
may be modulated in response to environmental stress to increase spontaneous 
mutation frequency, allowing for adaptation to hostile environments through 
increased protein diversity and flexibility (12). 
 Iron limitation results in tRNA undermodification by interfering with the 
conversion of i6A-37 to ms2i6A-37 (13). This process, the methylthiolation of A-37, 
is catalyzed by MiaB, which has received little attention relative to MiaA. MiaB 
acts as a monomer containing a [4Fe-4S] cluster under reducing conditions, with 
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[2Fe-2S] and [3Fe-4S] clusters present in anaerobic conditions (39, 40). The 
[4Fe-4S] cluster is bound by a cysteine from a CxxxCxxC motif contained in a 
radical S-adenosylmethionine (SAM) fold (39). A reducing equivalent from the 
[4Fe-4S]+ is then used to cleave SAM for the catalytic step of the methylthiolation 
of A-37. MiaB-like enzymes are widespread across phyla, and include bacterial 
proteins like Rim-O that function in the methylthiolation of the ribosomal S12 
protein, CDKAL1 proteins found in eukaryotes and some archaebacteria, and 
mammalian CDK5 subunits (27, 41). The breadth of mechanistic data on MiaA/B 
indicates conserved function across species of bacteria; however, there are 
potentially altered consequences downstream of the A-37 modification, which 
remain unexplored. 
 MiaA is known to govern expression of virulence determinants and stress 
response cascades in a variety of pathogens. In Salmonella enterica serotype 
Typhimurium, miaA mutants are defective at growth under oxidative stress and 
high temperature (42ºC)(7). In the plant pathogen Agrobacterium tumefaciens, 
mutants lacking miaA express decreased levels of the vir regulon, resulting in 
decreased virulence upon infection of red potato plants (22). MiaA also regulates 
virulence in Shigella flexneri by altering the translational efficiency of multiple 
genes, including the VirF transcriptional regulator (18, 19). Altered VirF 
expression leads to dysfunctional virulence in the form of decreased contact-
dependent hemolytic activity and delayed responses in focus plaque assays (18). 
The regulation of virulence-associated genes in multiple bacterial species 
suggests a conserved role for MiaA in the control of bacterial pathogenesis.  
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In this study, we test the role of MiaA and MiaB in the modulation of 
virulence and stress responses in uropathogenic Escherichia coli (UPEC). UPEC 
are the primary causative agents of urinary tract infections (UTIs), including both 
cystitis (bladder infection) and pyelonephritis (kidney infection) (21). During the 
course of infection, UPEC face many challenges, including colonization and 
survival in multiple host niches and stress conditions. Initially, UPEC traverse the 
urethra to gain access to the bladder lumen, where they can replicate in the 
urine. A fraction of the population then takes up residence within host bladder 
epithelial cells (35). Invasion of the host epithelium occurs via a zipper-like 
endocytic mechanism, resulting in delivery of UPEC into host late endosome-like 
compartments (20). Once internalized, UPEC may form quiescent intracellular 
reservoir populations thought to contribute to long-term bacterial persistence 
within the host (6, 20, 35). Alternatively, UPEC can exit the vacuole and replicate 
freely in the cytosol in association with host cytokeratin, forming intracellular 
bacterial communities (IBCs)(20). IBCs are large inclusions of bacteria that 
appear to act as dispersal sites for UPEC to re-infect the bladder lumen. UPEC 
face multiple stresses during this lifecycle. Some commonly encountered 
stresses include nutrient deprivation, redox stress in the form of oxygen and 
nitrogen radicals generated by cells, extreme pH, membrane stresses such as 
high salt concentrations, as well as many host immune effector cells and 
antimicrobial compounds (2, 3, 24, 26). Additionally, UPEC must be able to 
transition from sessile to motile forms, and vice versa, during the infectious 
process. Proper regulation of stress response pathways and sessile-to-motile 
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transitions is required for maximal virulence. Our knowledge of the UPEC life 
cycle offers a novel dimension in which to probe tRNA modification as it pertains 
to unique aspects of host-pathogen interactions during UTI. In this study, we 
show that varying levels of expression of MiaA, but not MiaB, can greatly impact 
multiple stress response pathways and virulence-related phenotypes in UPEC.  
 
Results 
Growth and metabolomics of UTI89∆miaA and UTI89∆miaB 
Knockouts of the miaA and miaB genes were generated in the reference 
UPEC cystitis isolate UTI89 using the lambda Red-recombination system (14). 
The knockout strains were tested for growth defects in modified M9 minimal 
media, Luria Bertani (LB) broth, and low pH morpholineethanesulfonic acid 
(MES)-buffered LB broth (LB-MES; pH 5.0) (Fig 6.1B-D). UTI89∆miaA grew 
similar to wild type in modified M9 minimal media but showed slight defects in 
LB-MES and LB broth, as previously noted with a K-12 E. coli strain (51), In 
contrast, the miaB mutant showed no overt growth defects in these media. It is 
known that miaA deletion can result in altered amino acid biosynthesis (4). Thus, 
we used gas chromatography/ mass spectroscopy to determine the levels of 47 
common bacterial metabolites in UTI89∆miaA during late exponential/stationary 
phase growth in M9 minimal media. This experiment uncovered broad scale 
metabolic changes, with significant differences in 27 of 47 metabolites despite 
normal growth of the mutant in this medium (Fig 6.1E). In this analysis, the 
changes in the mutant could not be attributed to one pathway, but rather 
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suggested vastly different metabolism in the knockout, consistent with known 
manipulation of metabolic pathways by MiaA (5).  
 
UTI89∆miaA exhibits growth defects in response to stressors 
The knockout strains were tested with exogenous stressors in growth 
assays. Challenge of UTI89∆miaA and UTI89∆miaB with the divalent cation 
chelator EDTA (1 mM) or the iron chelator desferal (10 mM) both caused no 
change in growth compared to wild type (Fig. 6.2A-B). This result is consistent 
with known up-regulation of MiaA by the addition of exogenous iron (12). The 
UTI89∆miaA strain grew poorly in a high salt medium (exogenous addition of 5% 
NaCl to standard LB broth) indicative of increased membrane stress (Fig. 6.2C). 
Challenge with the nitrosative stressor, acidified sodium nitrite (ASN), at 1 and 2 
mM resulted in significant growth defects for UTI89∆miaA, but not UTI89∆miaB 
(Fig. 6.2D-E). Further, growth in the presence of an oxidative stressor methyl 
viologen (MV), in both LB broth and modified M9 media, inhibited growth of 
UTI89∆miaA, but not the miaB mutant (Fig. 6.2D-I). Complementation of 
UTI89∆miaA with a plasmid containing miaA driven by its native promoter 
restored wild type level growth of the mutant in 1 mM MV (Fig. 6.2J). 
Interestingly, high-level expression of MiaA from an IPTG-inducible Ptac 
promoter hindered growth of UTI89∆miaA in the presence of MV, while leaky or 
low-level expression of MiaA rescued growth of the miaA mutant (Fig. 6.2K). 
These results indicate that too much MiaA can be even more detrimental to 
bacterial fitness than the complete absence of the enzyme. MiaB was not   
















Figure 6.2 UTI89∆miaA grows poorly under stress conditions in a dose-
dependent manner 
 
(A) Growth of UTI89∆miaA and UTI89∆miaB in LB with 1 mM EDTA, (B) 10 mM 
desferal, or (C) 5% NaCl. (D-E) Growth curve analysis of UTI89∆miaA in LB with 
1 and 2 mM acidified sodium nitrite. (F) Growth analysis of knockouts in LB with 
1 mM MV stress. Graphs in A-K show representative data consisting of four 
replicates from one of at least three independent experiments. Error bars were 














































































































Figure 6.2 Continued 
 
(G-I) Growth curve analysis of UTI89∆miaA and UTI89∆miaB in modified M9 
minimal media with 0.1, 0.2, and 0.3 mM MV. (J) Complementation of 
UTI89∆miaA growth defects in 1 mM MV using a plasmid (pMiaA2) containing 
MiaA driven by its native promoter (nMiaA). (K) Growth curve analysis of UTI89 
and UTI89∆miaA with an empty vector (pRR48) or plasmid containing miaA 
driven by an IPTG inducible promoter. IPTG was added at 10-fold dilutions from 
0 to 1000 µM. Graphs in A-K show representative data consisting of four 
replicates from one of at least three independent experiments. Error bars were 
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required for growth under oxidative stress and does not appear to be required for 
stress response in these assays. 
 
MiaA expression is altered in response to stress 
Growth assays indicated a role for MiaA in stress response to multiple 
stressors, leading us to question if MiaA levels are altered in response to 
stressful stimuli. UTI89∆miaA carrying a plasmid containing a C-terminal flag-
tagged MiaA (pMB5_MiaA-Flag; Table 6.1) under control of the native miaA 
promoter was assayed for MiaA expression following the addition of 1 mM MV to 







Strains   
E. coli   
UTI89 UPEC reference strain and cystitis isolate (10, 35) 




UTI89∆miaA UTI89 containing a chromosomal deletion of miaA This work 
UTI89∆miaB UTI89 containing a chromosomal deletion of miaB This work 
pKD3/4 Plasmids containing chloramphenicol (3) or 
kanamycin (4) resistance cassettes for use in 
lambda-Red recombination 
(14) 
   
Plasmids   
   
pRR48 IPTG inducible overexpression of protein coding 
sequence Apr 
(30) 
pMiaA1 IPTG inducible overexpression of MiaA Apr This work 
pMiaB1 IPTG inducible overexpression of MiaB Apr This work 
pACYC184 Low copy cloning vector Tetr Clmr  NEB 





pACYC184 containing C-Terminal Flag-tagged 
MiaA Tetr 
Submitted 
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bacterial cultures after reaching mid-log growth (OD600 = ~0.5). Within 60 min 
after addition of LB broth alone (100 µl into 5 ml cultures), levels of MiaA were 
notably elevated in the control samples as determined by Western blot analysis 
using anti-Flag (M2) antibody (Fig. 6.3A). This spike in MiaA expression was not 
observed following addition of MV, and MiaA levels remained depressed relative 
to the negative control up to the 90 min time point. MiaA levels varied less 
noticeably in UTI89 stationary phase cultures following challenge with MV (Data 
not shown). Desferal had no effect on MiaA levels, while the addition of high salt 
(5% NaCl) to mid-log cultures repressed expression of MiaA, similar to MV (Fig. 
6.3B). In contrast, EDTA elicited a substantial boost in MiaA levels. Interestingly, 
growth of UTI89 in MES-LB broth (pH 5.0) led to the appearance of slightly larger 
MiaA species that may represent modified forms of MiaA or products of read-
through errors beyond the artificial stop codon following the Flag-epitope tag 
sequence. 
 
Regulation of biofilm development and motility by MiaA 
The effects of MiaA expression on bacterial behavior were tested using 
several assays, including in vitro biofilm formation and motility assays. Microtiter 
plate-based biofilm assays performed in modified M9 minimal media at 30°C 
indicated significant defects for both UTI89∆miaA and ∆miaB compared to the 
wild type strain (Fig. 6.4A). UTI89∆miaA was also defective at biofilm formation 
at 37°C (Data not shown). As seen with growth assays in the presence of MV 
(Fig. 6.2K), low-level expression of recombinant MiaA rescued the ability of 




Figure 6.3 MiaA protein level responds to stressors 
 
(A) Overnight grown bacteria were subcultured into fresh media and incubated 
for 2.5 h before addition of 1 mM MV resuspended in LB broth. LB broth alone 
(volume??) was used as a negative (-) control. Western blot analysis was 
performed using anti-Flag M2 antibody to MiaA-Flag at time points after stress 
addition. (B) Western blot analysis of 60 m time point as described above, after 
stressor addition with 1 mM ASN, 1 mM EDTA, 5% NaCl, and 10 mM desferal or 
control media. Loading controls for A-B are non-specific bands using a bacterial 
alkaline phosphatase antibody. Data are representative data from at least 3 
independent experiments. It is important to note that growth of these strains was 
not affected by the stressors in these assays.   
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Figure 6.4 MiaA/B differentially regulate UPEC motility and biofilm 
formation 
 
(A-C) In vitro biofilm formation assays in plastic dishes were measured using 
crystal violet as described in the methods. (A) Biofilm growth of mutants without 
complementation. (B-C) The strains utilized contain empty vector or IPTG-
inducible overexpression of MiaA/B. Data is the combination of at least 3 
separate experiments in quadruplicate (D-E) A time course of movement on 
swim motility plates (0.2% agar). Graph is from three independent experiments 
done in triplicate. Error bars are standard error of the mean with *= P < 0.05 (F-
G) Swarm motility of UTI89∆miaA with complementation or overexpression. In F 
UTI89 and UTI89∆miaA contain an empty vector (pACYC184) or a plasmid 
containing MiaA driven by its native promoter (pMiaA2) for complementation. 
Panel G shows UTI89 and UTI89∆miaA with an empty vector (pRR48) or a 
plasmid containing IPTG inducible MiaA (pMiaA1) for overexpression. F-G 
photos are of representative data from one of three independent experiments. 
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UTI89∆miaA to form biofilms, whereas high-level induction of MiaA was inhibitory 
(Fig. 6.4B). Importantly, the biofilm defect observed with a UTI89∆miaA was not 
rescued by complementation with Hfq, an RNA chaperone that is encoded 
downstream of miaA on the UTI89 chromosome, further confirming that the 
observed phenotypes are specifically attributable to disruption of the miaA gene 
(Data not shown). The biofilm defect associated with the miaB mutant was 
rescued by complementation using a plasmid encoding IPTG-inducible miaB, but 
unlike MiaA, higher levels of MiaB expression correlated with improved biofilm 
formation (Fig. 6.4C).  
The ability of bacteria to move within their environment is key to their 
survival within the host. Motility assays were performed in vitro to explore the 
regulation of bacterial movement by MiaA expression. Swim motility plates are 
used to determine the ability of bacteria to move through agar, whereas swarm 
motility plates test the ability of the bacteria to undergo a differentiation process 
before moving in a social manner on the surface of a slightly higher concentration 
agar. In swim plates, the motility of UTI89∆miaA was significantly delayed 
relative to the wild type strain, whereas no defect was observed with 
UTI89∆miaB (Fig. 6.4D and E). On swarm plates, UTI89∆miaA displayed 
drastically increased motility compared with wild type UTI89 (Fig. 6.4F and G). 
Expression of MiaA off its native promoter from a low-copy number plasmid 
(pMiaA2 constructed using pACYC184) reduced the swarming of UTI89∆miaA to 
near-wild type levels (Fig. 6.4F). In contrast, high-level expression of MiaA from 
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an IPTG-inducible promoter almost completely inhibited swarming by both the 
wild type and miaA mutant strains (Fig. 6.4G).   
 
MiaA promotes bacterial colonization of the bladder 
In cell culture-based assays UTI89∆miaA and UTI89∆miaB were able to 
bind, invade, and survive within host cells normally (Fig 6.S1). The ability of 
these mutants to colonize bladder cells in vivo was assessed using a well-
established mouse UTI model system (6, 30). Mutant and wild type strains were 
inoculated via transurethral catheterization into adult female CBA/J mice, and 
bacterial titers present in the bladders were determined 3 d later. In these non-
competitive assays, the miaB mutant showed no obvious defect relative to wild 
type UTI89 (Fig.6.5A), while the miaA mutant was significantly attenuated (Fig. 
6.5B). Defects in bladder colonization by UTI89∆miaA where apparent by 6 h 
postinoculation (Fig. 6.5C), although this mutant was still able to form similar 
numbers of IBCs as the wild type strain (data not shown).  At 9 d post-
inoculation, UTI89∆miaA still had significantly decreased titers compared to wild 
type (Fig. 6.5D), suggesting that UTI89 required miaA to effectively establish 
and/or maintain longer-lived intracellular reservoirs. To address this further, 
infected mice were treated with the cell-impermeable antibiotic gentamicin on 
days 4, 5, and 6 postinoculation in order to eliminate any extracellular bacteria 
residing in the lumen of the bladder. After a 3 d recovery period (day 9 post-
inoculation), mice were sacrificed and the number of bacteria present within the 
bladder tissue enumerated. This experimental setup enables quantification of  














Figure 6.5 MiaA promotes UPEC infection of a murine host  
 
(A-E) Mice were infected with 10^7 CFU of UTI89∆miaA or ∆miaB. Mice were 
sacrificed at 6 h, 3 d, or 9 d postinfection as indicated and bladders titers were 
enumerated. (E) Reservoir assays were performed as described in the materials 
and methods with mice sacrificed at 9 d. Each panel in A-E is 11 mice from two 
separate independent experiments. P values were determined by Mann Whitney 
U test with *= P < 0.05. (F) Antibiotic persistence assays were performed by 
subculturing overnight bacterial cultures into fresh media containing antibiotic for 
6 hours followed by titering of bacterial levels. Each antibiotic challenge 
compares UTI89∆miaA and UTI89∆miaB to the wild type UTI89 strain. Data are 
the combination of 3 separate experiments with SEM. *= P < 0.05. 
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bacterial populations (or reservoirs) that are, or were, contained within 
intracellular niches within the bladder urothelium during the gentamicin 
treatments (6). In these assays, UTI89∆miaA was recovered significantly less 
frequently than the wild type strain (Fig. 6.5E), reflecting the overall decreased 
abundance of the miaA mutant at the 9 d time point (Fig. 6.5D).  
 
miaA promotes persistence during antibiotic challenge 
E. coli and other bacteria are often able to develop dormant, stress- and 
antibiotic-resistant cells known as persisters, which may facilitate bacterial 
survival within hostile host environments such as the bladder (29). One way to 
assess persister cell development is to challenge bacteria with the effects of 
miaA and miaB on persister cell development by UTI89 were assessed using 
standard assays (28). Wild type and mutant bacteria were grown to stationary 
phase, diluted 1:10 into fresh media ± ampicillin (20 µg/mL), ofloxacin (10 
µg/mL), or gentamicin (10 µg/ml), and incubated at 37°C for 6 h prior to plating. 
In these assays a ~7 fold increase in survival of UTI89∆miaA after treatment with 
the DNA gyrase inhibitor ofloxacin was observed (Fig 6.5F), but no significant 
effects were seen with the other two antibiotics tested. UTI89∆miaB was not 
significantly different from wild type UTI89 in any case. The aminoglycoside 
gentamicin killed most of the bacteria, regardless of miaA presence,  making it 
unlikely that antibiotic-resistant persisters account for the bacterial populations 
that remain in the bladder following in vivo gentamicin treatments (see Fig. 6.5E).  
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The α-hemolysin toxin is not expressed in a miaA knockout 
During growth on blood agar plates, we noticed that UTI89∆miaA fails to 
lyse red blood cells like the wild type strain. Complementation of UTI89∆miaA 
with a plasmid encoding miaA driven by its native promoter restored hemolytic 
activity to wild type levels (Fig. 6.6A, top panels and data not shown). These 
observations are consistent with literature showing that Shigella flexneri contact-
dependent hemolytic activity is decreased when miaA is deleted, a phenomenon 
that was linked to decreased expression of the master virulence regulator VirF in 
this pathogen (18). The hemolytic activity of UTI89 is attributable to an unrelated 
exotoxin, α-hemoylsin (HlyA). This toxin is not necessary for UTI89 to colonize 
and persist within the murine urinary tract, but it does enhance the ability of 
UPEC strains to damage host tissues and immune effector cells ((16, 33, 48, 49) 
and data not shown). By western blot, we found that UTI89∆miaA does not 
express HlyA (Fig. 6.6A, bottom panels). However, qRT-PCR indicated that 
deletion of miaA results in significantly increased levels of hlyA transcript (Fig 
6.6B). This correlated with enhanced transcript levels of hlyD, a gene within the 
hly operon that encodes a translocator for the HlyA toxin (42). MiaA therefore 
promotes the expression of HlyA via a posttranscriptional mechanism. A possible 
reason for the lack of HlyA expression is that frameshift errors accumulated 
during the translation in the absence of miaA may preclude efficient production of 
large proteins like HlyA (1025 amino acids). However, this is unlikely, as another 
protein of identical length (β-galactosidase, encoded by lacZ) is expressed at wild 
type levels by UTI89∆miaA, as determined by growth on MacConkey agar plates  


















Figure 6.6 MiaA contributes to α-hemolysin formation, possibly through 
manipulation of host chaperone production 
 
(A) Hemolytic activity of UTI89 and UTI89∆miaA on blood agar plates and 
visualized by Western blot using an anti-α-hemolysin antibody courtesy of Rod 
Welch. Representative image from one of at least three independent 
experiments. (B) qRT-PCR analysis of levels of HlyA and HlyD, (C) bacterial 
chaperones, (D) proteases, and (E) sigma factors. Expression was normalized to 
the housekeeping sigma factor RpoD. Experiments are combinations of data 
from three independent RNA preparations, each with two technical repeats in 
duplicate. (F) Expression of periplasmic chaperone activity using a CpxP-GFP 
reporter for the CpxP periplasmic stress response protein. Experimen F is data 
collected from three independent experiments in triplicate. Graphs B-E show 
SEM with *= P < 0.05. 
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(data not shown). Of note, the lacZ and hlyA protein coding sequences contain 
similar fractions of both rare codons and codons recognized by tRNAs that are 
modified by MiaA. UTI89∆miaB showed no defects in hemolytic activity or lactose 
fermentation, suggesting that loss of HlyA expression in the miaA mutant is due 
to decreased prenylation of A-37 and not downstream modifications.  
 
MiaA mutants show altered chaperone and protease levels 
The ablation of HlyA expression and the overall decreased fitness of 
UTI89∆miaA suggested that this mutant might have multiple defects in basic 
housekeeping processes, including perhaps general protein chaperone and 
protease activities. In support of this possibility, we found by qRT-PCR that 
expression of the cytosolic chaperone GroEL and DnaK were substantially 
downregulated in the miaA mutant (Fig. 6.6C). No significant changes were 
observed with expression of genes encoding the proteases Lon or ClpX (Fig. 
6.6D). Likewise, expression of the stress response sigma factors RpoS and 
RpoH were similar in wild type and miaA mutant bacteria (Fig. 6.6E). However, 
activation of the Cpx envelope stress response system, as determined by use of 
a CpxP-GFP promoter fusion, was modestly, though significantly reduced in the 
miaA mutant (Fig. 6.6F). CpxP acts as a periplasmic chaperone as well as a 
negative regulator of the Cpx two-component system, regulating the expression 
of additional periplasmic chaperones and nearly 100 other proteins (50). MiaA 
therefore affects the expression of at least three key chaperones within UTI89, 
meaning that it has a much greater role as a posttranscriptional regulator of 
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Classically, the modification of tRNA residues was thought to be required 
strictly for correct incorporation of amino acids into growing polypeptide chains. 
Recent studies suggest that in addition to optimization of translation, tRNA 
modification is a dynamic process that can be used to modulate cellular 
physiology, stress responses, and virulence (9). MiaA and MiaB both add 
modifications to A-37, adjacent to the anticodon within UNN-encoding tRNA 
molecules found in E. coli and many other bacteria (27, 38). The MiaA tRNA 
prenyltransferase adds a prenyl group onto the UNN subset of tRNA, which 
promotes reading frame maintenance and translational fidelity. MiaB then 
methylthiolates A-37 to its final form, completing the modification of A-37. 
Regulation of tRNA modification reactions has been posited as a means to 
quickly adjust large-scale bacterial responses to stimuli. In particular, previous 
literature has suggested a role for miaA expression in fine-tuning cellular 
adaptation under stressful conditions through regulation of protein diversity (12). 
In this model, increased expression of MiaA would promote translational fidelity 
while limiting protein diversity (stringent regulation of correct amino acid 
incorporation). In contrast, decreased expression of miaA would reduce 
translational fidelity and frameshifting, allowing for more error-prone translation 
and subsequent diversification of expressed proteins in stressful environments. 
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We sought to define the functional relevance of MiaA to the stress resistance and 
virulence capacity of UPEC, making comparisons with MiaB when appropriate. 
 In vitro growth assays indicated that both MiaA and MiaB were 
dispensable to the ability of UPEC to replicate within modified M9 minimal media 
and LB broth. However, deletion of miaA, but not miaB, greatly reduced bacterial 
fitness when challenged with oxidative, nitrosative, and high salt stresses. These 
data demonstrate distinct functions for the two different modifications of A-37 
mediated by MiaA and MiaB, with MiaA being much more critical to bacterial 
survival under stress. Interestingly, while low-level expression of MiaA restored 
the stress resistance of the miaA mutant, overexpression of MiaA was 
detrimental. The benefit of MiaA expression in stressful situations is therefore 
sensitive to dosage effects. This finding is consistent with the idea that tRNA 
modifications are not all-or-nothing events. Rather, shifts in the prevalence of 
specific modifications, such as A-37 prenylation mediated by MiaA, can help 
optimize bacterial responses to stress by affecting the fidelity of translation and 
ultimately the spectrum of available wild type and mutant proteins.  
 Dosage effects of MiaA expression seen in growth assays with UPEC 
under stress were also observed in biofilm and swarm motility assays. In 
contrast, the miaB mutant was found to be defective only in biofilm formation, 
and overexpression of MiaB was not detrimental. These results suggest that 
MiaA is required for optimal bacterial fitness under diverse conditions, while 
conditions that require MiaB are more limited. Combined, these data indicate that 
MiaA acts as a global stress response regulator that can significantly alter UPEC 
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behavior and stress resistance. Consistent with these results, expression of MiaA 
was shown to be differentially responsive to diverse stresses, including MV and 
high salt.   
 In line with its apparent role as a global stress response regulator, MiaA 
was found to also control expression of the pore-forming toxin HlyA. Deletion of 
miaA ablates translation of HlyA, even though hlyA transcripts are significantly 
elevated. Previous work has highlighted HlyA regulation by leuX-encoded 
tRNA5Leu (17). This tRNA can be modified by MiaA, suggesting that the observed 
phenotypic defects associated with UTI89∆miaA may be due to a lack of 
modified tRNA5leuX. However, it has been reported that deletion of leuX  does not 
affect HlyA transcript levels, even though HlyA protein expression is reduced 
(17). Furthermore, a UPEC mutant lacking leuX is defective in its ability to bind 
and invade BECs and subsequently forms IBCs (23), whereas miaA is 
dispensable for all of these activities. These data suggest that leuX is not the 
only factor regulated by MiaA that can contribute to the phenotypic defects we 
observed with UTI89∆miaA. For example, we found that deletion of miaA results 
in decreased expression of at least three key chaperone proteins and regulatory 
proteins - DnaK, GroEL, and CpxP. Modulation of these factors by MiaA can 
conceivably have global effects on the stress resistance and virulence potential 
of UPEC. Results from a small metabolomics screen lead to a similar conclusion, 
showing that MiaA expression can have profound effects on the spectrum of 
metabolites available to UPEC, which may in turn affect bacterial resistance to 
oxygen radicals and other stresses.  
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 In a murine UTI model, UTI89∆miaA, but not the miaB mutant, was 
significantly attenuated in its ability to colonize and persist within the bladder. 
These in vivo defects appear to include the reduced ability of UTI89∆miaA to 
establish and maintain intracellular reservoirs within the bladder mucosa. During 
the course of a UTI, UPEC will encounter multiple stresses within the urinary 
tract (2, 24, 26). Motility and the ability to form biofilms are thought to aid 
bacterial survival within this harsh host environment (44). The effects of MiaA on 
these processes, as well as many others, likely explain why MiaA is necessary to 
the optimal survival of UPEC within the urinary tract. It is likely that rapidly 
changing conditions within the host necessitate altered levels of MiaA expression 
and subsequent tRNA modifications, as appears to be the case upon exposure of 
UPEC to stresses in vitro. How changes in MiaA levels influence the protein 
landscape and pathogen adaptability is not yet entirely clear and will require 
additional approaches like ribosomal profiling to discern in detail (25). In total, 
this work offers a compelling case study of how pathogens can integrate 
rudimentary metabolic genes to modulate and refine stress resistance and 
virulence-associated phenotypes.  
 
Materials and Methods 
Bacterial strains and plasmids 
Strains used in this manuscript are described in Table 6.1. Mutant strains 
were constructed in the human cystitis isolate Escherichia coli strain UTI89 using 
the lambda Red recombination system and primers list in Table 6.2 as previously 
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Table 6.2 Oligonucleotides employed during the study 
 
Primer Namea Sequence (5’-3’)b, c, d 
MiaA-pRR48-F CGCGCTGCAGATGAGTGATATCAGTAAGGCG 
MiaA-pRR48-R CGGCGGTACCTCAGCCTGCGATAGCACCAAC 










































a F, forward Primer; R, reverse Primer; KO, knockout primer; Conf, confirmation 
primer,  b Universal Primer sequence underlined,  c Added restriction sites 
underlined,  d Flag tag and linker sequence in bold 
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described (14). The chloramphenicol cassette flanked by LoxP sites was 
amplified from plasmid pKD3. Primers for amplification of chloramphenicol were 
designed with overhanging ends with 39 bp of homology to the 5’ and 3’ ends of 
target knockout sites. PCR products were then introduced by electroporation into 
UTI89 pkm208, a strain containing a plasmid encoding the IPTG-inducible 
recombinase. Knockouts were verified by PCR by using flanking primers specific 
for target genes.  
 
Growth assays 
UTI89 and its derivatives were grown from frozen stocks in either Luria-
Bertani (LB) broth or M9 minimal medium (6 g/liter Na2HPO4, 3 g/liter KH2PO4, 1 
g/liter NH4Cl, 0.5 g/liter NaCl, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% glucose, 
0.0025% nicotinic acid, 0.2% casein amino acids, and 16.5 µg/ml thiamine in 
H2O) at 37°C overnight in loosely capped 20-by-150-mm borosilicate glass tubes 
with shaking at 225 rpm at a 30º angle. Overnight cultures were diluted 1:100 into 
100-well honeycomb plates and assayed for growth using a Bioscreen C 
instrument (Growth Curves USA). Stressors were added to subcultured bacteria 
to reach the appropriate final concentration (0.1, 0.2, 0.3, or 1.0 mM MV; 1.0 or 
2.0 mM ASN; 10 mM desferal; 1 mM EDTA; 5% additional NaCl). LB-MES (pH 
5.0) media was used for low pH and ASN treated samples. Antibiotics were 
added when applicable for the overnight growth but not for subsequent growth 
assays.  
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Metabolomics sample preparation 
Chemicals and reagents were of the highest purity and purchased from 
Sigma-Aldrich except for MSTFA was purchased from Pierce and 2-methylcitrate 
was purchased from CDN isotopes. Six biological replicates of each strain were 
used per experiment. The cultures were grown to an OD600 of 1 and harvested by 
centrifugation and the pellet frozen. To each frozen pellet was added 5 ml of 
boiling 75% EtOH (aqueous), vortexed then incubated at 90°C for 5 min. Cell 
debris was removed by centrifugation at 5000 x g for 3 m. The supernatant was 
removed to new tubes and dried en vacuo.  
 
GC-MS analysis 
All GC-MS analysis was performed with a Waters GCT Premier mass 
spectrometer fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 
autosampler. Dried samples were suspended in 40 µl of a 40 mg/ml O-
methoxylamine hydrochloride in pyridine and incubated for one hour at 30°C. To 
autosampler vials was added 20 ul of this solution with MSTFA added using the 
autosampler and incubation for 30 min at 37°C with shaking. One ul of sample 
was injected to the inlet which was held at 250°C. The gas chromatograph an 
initial temperature of 95°C for 1 min followed by a 40°C/min ramp to 110°C and a 
hold time of 2 min. This was followed by a second 5°C/min ramp to 250°C then a 
third ramp to 350°C and a final hold time of 3 min. A 30 m Restek Rxi-5 MS 
column with a 5 m long guard column was employed for analysis. Data were 
collected by MassLynx 4.1. Data analysis for known metabolites was performed 
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using QuanLynx. To find possible unknown metabolites MarkerLynx was used for 
peak picking and these data were exported to SIMCA-P ver. 12.0.1 where PCA 
and PLS-DA analysis was performed. 
 
Western blot analysis 
Bacterial cultures were grown to desired O.D. (~1.0-1.2) and mixed 
directly with 2x sample buffer (without β-mercaptoethanol for non-reducing gels). 
Samples were then vortexed for 30 s and boiled for 5 m (heated to 60ºC for non-
reducing gels). Samples were resolved in 12.5% acrylamide using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
subsequently transferred to PVDF membranes (Millipore) for Western blot 
analysis. All antibody incubations were performed in 2.5% powdered milk, 0.1% 
Tween-20 in Tris-Buffered Saline (pH 7.4). Blots were incubated with Mouse anti-
Flag M2 (1:3000; Sigma) or Rabbit anti-Hemolysin A (1:800: Rod Welch) 
overnight at 4ºC, followed by a 30 m incubation with secondary anti-mouse/rabbit 
HRP-conjugated IgG antibody (1:3,000; Amersham Biosciences). Blots were 
then washed, developed using the SuperSignal West 1 Pico (Pierce), and 
exposed to CL-XPosure Film (Pierce). To ensure that equivalent amounts of 
protein from each sample were loaded, duplicate gels were stained using 
GelCode Blue (Pierce) and/or blots were re-probed using Rabbit anti-E.coli 
antisera (1:2,000; Iowa Hybridoma Bank?). 
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Biofilm assay 
In vitro microtiter plate-based biofilm assays were performed as previously 
described. Briefly, UTI89 was diluted 1:100 from overnight shaking cultures into 
M9 medium, and triplicate 100 µl samples in 96-well pinchbar flat-bottomed 
polystyrene microtiter plates with lids (Nunc) were incubated for 48 h without 
shaking at 30°C. Nonadherent bacteria were then removed by washing twice with 
H2O prior to addition of crystal violet (150 µl of a 0.1% solution in water; Sigma-
Aldrich). After a 10 min incubation at room temperature, the wells were rinsed 
twice with H2O and air dried. Dimethyl sulfoxide (200 µl; Sigma-Aldrich) was then 
added to each well, and the plates were shaken vigorously for 15 min on an 
orbital shaker to solubilize the dye. A 150 µl aliquot from each well was 
transferred to a fresh microtiter plate, and A562 was measured using a Synergy 
HT multidetection microplate reader (BioTek Instruments, Inc.).  
 
Motility assays 
Bacterial swarm motility was determined by inoculating 0.2% agar plates 
with a toothpick dipped into an overnight culture of each strain. Care was taken 
to break the surface but not touch the bottom of the plate, to avoid initiating twitch 
motility. Plates were incubated face up at 37ºC for ~12 hours and the diameter of 
spreading was measured every 2 h. Values are from three separate experiments 
done in quadruplicate. Swarm motility assays were performed using 0.5% Eiken 
agar plates supplemented with 0.5% glucose. Five µL of bacteria were spotted 
on the surface of the plate and allowed to swarm overnight (16 h) at 37°C. 
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Invasion, association, and replication assays 
UTI89 was grown at 37°C for 48 h in static LB broth to induce type 1 pilus 
expression. Triplicate sets of confluent 5637 bladder epithelial cell monolayers 
grown in 24-well tissue culture plates were infected with UTI89 using a 
multiplicity of infection of ~15 bacteria per host cell. To facilitate and synchronize 
bacterial contact with the host cells, plates were centrifuged at 600 x g for 5 min 
at room temperature at the start of infection (Beckman Allegra 6 Centrifuge). 
After a 2 h incubation at 37°C, samples were washed three times with PBS 
containing Ca2+ and Mg2+ (PBS2+) to remove any nonadherent bacteria. Wells for 
adherence and total growth assays were collected at this time point and lysed in 
PBS plus 0.4% Triton X-100, and bacteria present within the lysates were 
enumerated by plating serial dilutions on LB agar plates. Monolayers for invasion 
and intracellular replication assays were then incubated for another 2 h with 
complete RPMI medium plus 100 µg/ml of gentamicin to kill extracellular 
bacteria. Monolayers for invasion assays were collected at this time point of 4 h 
and processed as described above. For intracellular replication assays, 
additional washes with PBS2+ were performed, followed by addition of fresh 
medium containing a lower concentration of gentamicin (10 µg/ml). Incubations 
were continued for another 14 h. This submaximal concentration of gentamicin 
was used to prevent extracellular growth of UPEC while limiting possible leaching 
of the antibiotic into the host cells during longer incubations (13). After final 
washes in PBS2+, host cells were again lysed as described above in PBS plus 
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0.4% Triton X-100, with bacteria enumerated by plating serial dilutions on LB 
agar plates.  
 
Mouse infection experiments 
Seven- to 8-week-old female CBA/J mice (Jackson Laboratory) were 
anesthetized with isoflurane by inhalation and slowly inoculated via transurethral 
catheterization with 50 µL of the bacterial suspension (~107 CFU from 24 h static 
LB broth cultures of UTI89) in PBS as previously described. Bacterial reflux into 
the kidneys using this procedure is rare, occurring in less than 1% of the test 
animals. At 1, 3, or 9 days postinoculation, mice were sacrificed and bladders 
were harvested aseptically, weighed, and homogenized in 1 mL PBS containing 
0.025% Triton X-100. Bacterial titers within the homogenates were determined by 
plating serial dilutions on LB agar plates. Eleven mice total, from two 
independent experiments, were used for each condition tested. Previous 
published results indicate no need for mock-infected mice to be housed in cages 
with the infected. Reservoir populations were determined by infecting mice as 
described above. At 3 days post infection, mice were treated for 3 consecutive 
days with one dose of Gentamicin (200 µg) subcutaneously. Control animals 
received subcutaneous injections of PBS. All antibiotics were delivered in 50 µl 
volumes. Mice were sacrificed 3 d after the final antibiotic treatment and treated 
as described above.  
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Persister assays 
Persister cell assays were performed as previously described. Briefly, an 
overnight bacterial culture was subcultured 1:10 into fresh media containing 
appropriate antibiotic (ampicillin (20µg/mL), ofloxacin (10µg/mL), and gentamicin 
(10µg/ml)). An aliquot of the input was titered for reference. Cultures with 
antibiotics incubated shaking at 37ºC for 6 h before bacteria were titered.  
 
Hemolytic activity phenotypic assays 
Hemolytic activity was determined by streaking bacteria onto 5% sheep’s 
blood agar plates and incubated for 18 h at 37˚C (Sigma-Aldrich). Plates were 
visually observed for presence of a halo of red blood cell lysis around the 
bacterial growth. β-galactosidase activity was qualified by pink growth on 
MacConkey agar plates overnight at 37˚C (Sigma-Aldrich). pH of bacterial growth 
media was determined by applying culture bacteria to pH strips (Sigma-Aldrich).   
 
Quantitative reverse transcriptase polymerase chain reaction 
Total RNA was collected from bacterial cultures (grown to O.D. ~1.0-1.2) 
using the Norgen Total RNA Isolation Kit (Norgen Biotek) and treated twice with 
Turbo DNase (Life Technologies). Superscript III using random hexamers was 
used to reverse transcribe RNA into cDNA (Life Technologies). qRT-PCR was 
performed using Syber Green Mix and primers listed in Table 6.2 and run on a 
Lightcycler 480 machine (Roche). Reactions were set up with and without RT as 
a control. All primer sets were optimized for use, and run on a 1.5% agarose gel, 
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stained with ethidium bromide, and imaged on a GelDoc (Bio-Rad Technologies), 
to verify the presence of only one band. qRT-PCR results were normalized to the 
housekeeping sigma factor, RpoD, transcript level.  
 
Statistical analysis 
P values were determined by Student’s t Test and Mann-Whitney U tests 
performed using Prism 5.01 software (GraphPad Software). Values of less than 
0.05 were defined as significant.  
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Figure 6.S1 miaA/B mutants exhibit no effects on host cell invasion, 
association, or intracellular replication 
 
(A-C) Cell culture assays were performed using 5637 bladder epithelial 
carcinoma cells to test for bacterial association, invasion, and replication within 
host cells using the miaA knockout and (D-F) miaB knockout. Bar graphs in A-F 
are from three independent experiments performed in triplicate with error bars 
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The research presented in these chapters provides insight into UPEC 
pathogenesis during a UTI, specifically in regards to the establishment and 
maintenance of the reservoir population responsible for chronic and recurrent 
infections.  
 In Chapter 2, the susceptibility of UPEC strain UTI89 to antibiotic 
challenges was tested in vitro and during a murine UTI. While most of the tested 
antibiotics killed UPEC in broth cultures, many were ineffective against 
intracellular UPEC in a bladder cell culture model. Similarly, a large percentage 
of antibiotics were unable to affect UPEC growing in biofilms on plastic dishes. A 
few host cell-permeable antibiotics did prove promising in these assays and were 
tested in a mouse model of UTI. Of the antibiotics tested in vivo (gentamicin, 
ciprofloxacin sparfloxacin, and fosfomycin), all were able to effectively sterilize 
the urine, but none completely eliminated the reservoir populations associated 
with the bladder tissue. Previous studies suggested that the reservoir population 
consists of an intracellular subset of UPEC (13, 24, 30). However, in this study 
IBCs were sensitive to treatment with the cell-permeable antibiotic sparfloxacin 
ex vivo, suggesting that IBCs are not the primary reservoir. Rather, the reservoirs 
likely consist of small bacterial clusters, or single bacteria, distributed throughout 
the urothelium (13, 24, 30). The robust barrier function of the urothelium, coupled 
with the quiescent nature of the UPEC reservoirs, limits the effectiveness of 
antibiotics (3). The research described in Chapter 2 laid the framework for the 
rest of this thesis by further defining the confounding issues surrounding 
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treatment of recurrent UTIs, namely resistance to antibiotic treatment through 
bacterial internalization and bacterial quiescence in the host epithelium.  
The existence of UPEC reservoirs provides a roadblock to efficacious 
treatment options (20, 30). Several hypothetical approaches could solve the 
issue of UPEC persistence in the bladder. An effective UPEC vaccine could 
promote clearance of bacterial infections by UPEC; however, ongoing research 
in this field has so far not yielded vaccines that are effective in human patients 
(28, 34). A second strategy would be to treat infected bladders with a 
combination of antibiotics and an epithelial cell exfoliant to disrupt the barrier 
function of the urothelium and permit penetration of antibiotics to underlying 
tissues: a technique explored in Chapter 3. A third possible approach, as outlined 
in Chapters 4 through 6, is to target the mechanisms used by UPEC to persist in 
the urinary tract, specifically in regards to regulation of stress response and 
virulence.  
 Chapter 3 unveils a therapeutic strategy to dislodge UPEC reservoirs from 
the bladder epithelium through the use of chitosan, a chitin-based bladder 
exfoliant. Hultgren and colleagues recently took a similar approach using 
protamine sulfate to induce exfoliation of bladder cells (25, 26). Unfortunately, 
significant inflammation, tissue destruction, and pain associated with use of 
protamine sulfate made this approach an impractical treatment option for 
clearance of UPEC reservoir populations in human patients. In contrast, chitosan 
disrupts epithelial cell tight junctions to trigger exfoliation of primarily the 
superficial cell layer in the mammalian bladder with little inflammation (19, 21, 
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33). Chitosan is also approved for clinical use in humans as a drug-carrier 
molecule (4). In this study infected mice were treated with a combination of 
chitosan and the host cell-permeable antibiotics, sparfloxacin or ciprofloxacin, for 
seven days. This combination therapy almost completely eliminated the reservoir 
population from the bladder, yet many mice still exhibited recurrent or relapsing 
infections as measured by urine titers over the course of two weeks following 
treatment. A chitosan and sparfloxacin combination treatment was, however, 
significantly more effective at inhibiting recurrence compared to control untreated 
mice. Although promising as a therapeutic, administration of chitosan to the 
bladder has a damaging effect on the epithelium and potentially offers pathogens 
increased opportunity to invade underlying tissues. Furthermore, the efficacy of 
chitosan use should be tested in additional mammalian model systems, as well 
as against alternative pathogens. For example, chitosan has been shown to 
trigger exfoliation of superficial bladder epithelial cells in pig bladders, but no 
human studies have confirmed the effectiveness of chitosan as an exfoliant (19, 
21). Secondly, therapies effective against one UPEC strain may fail to eradicate 
strains of Klebsiella or other common causes of UTI, which would render this 
treatment less effective. Incubation of UPEC in chitosan also resulted in 
increased inter-bacterial connections and extracellular matrix-like material as 
observed by SEM and immunofluorescence, likely contributing to increased 
biofilm formation and host-cell association. The increased association of UPEC 
with host cells is concerning, since increased adhesion likely promotes invasion, 
propagating the infection. Invasion assays did, however, suggest a decrease in 
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the rate of epithelial cell invasion in these assays. Taken together, chitosan-
based therapies appear promising; but much work remains to elucidate their full 
potential for treatment of UTI. 
The second major aim of Chapter 2 was to use chitosan as a tool to probe 
the contribution of underlying tissues in reservoir formation and recurrence. It 
was shown that UPEC invade underlying tissues as efficiently as the superficial 
epithelium, and both superficial epithelia and underlying tissues contribute to 
formation of the reservoir population. Imaging and mouse infection experiments 
also suggested a resurgence of UPEC titers in the urine after chitosan treatment. 
Figure 7.1 depicts a model of UPEC pathogenesis, synthesizing the data 
presented here with decades of UTI study. According to the model, UPEC invade 
superficial epithelial cells triggering exfoliation of large swaths of the urothelium 
(11, 23). Rarely, UPEC are able to invade underlying epithelial tissues to 
establish additional quiescent intracellular reservoir populations, where the 
bacteria reside metabolically inactive encased in host actin (12, 13). Upon 
turnover or damage to superficial bladder epithelial cells, quiescent intracellular 
UPEC reservoirs move towards the apical surface, by traveling as passengers 
within differentiating underlying and intermediate cells. UPEC then recognize the 
differentiation of superficial bladder epithelial cells as an environmental cue to 
replicate intracellularly and form an IBC; a possible signal being the loss of high 
actin expression in differentiated superficial epithelial cells (13). The IBC then 
releases a bolus of UPEC into the bladder lumen to initiate a new round of 
infection (2, 18, 23). This model posits the periodic resurgence of UTI in 















Figure 7.1 Model of UPEC Pathogenesis  
 
(1.) UPEC gain entry to the bladder lumen where they replicate rapidly to high 
numbers in the urine. (2.) The infrequent event of cellular invasion occurs to 
create an intracellular UPEC niche. (3.) Shear forces from urine flow remove the 
majority of the non-adherent bacteria from the bladder, while UPEC begins to 
replicate intracellularly to form an IBC before exit to the cytosol. (4.) IBC 
formation triggers exfoliation of host cells to remove infected cells, allowing for 
infection of underlying tissues. (5.) The host epithelium is repaired to regain 
barrier integrity, effectively establishing persistent, quiescent, intracellular UPEC 
reservoirs in the underlying epithelium encased in host actin. (6) UPEC act as 
passengers in host epithelial cells and are trafficked to the surface during 
superficial cell differentiation. Upon arrival at the surface, UPEC break out of the 
host cell through IBC formation to reinoculate the bladder lumen, triggering 
subsequent rounds of infection. 
	  	   	  














































	  	   	  
217	  
mammalian hosts as being caused primarily by the slow turnover of host 
superficial cells (17). It also reaffirms data suggesting that IBCs are a facilitator of 
productive infection through inoculation of the bladder with an acute burst of 
bacteria (2, 18, 24). Chapters 4 through 6 aimed to elucidate mechanisms 
underlying the establishment and maintenance of the UPEC reservoir 
populations. In order to establish an infection in the urinary tract, pathogens must 
survive challenge from a wide range of stressors, including low pH challenge, 
nitrosative and oxidative stressors, immune challenge, and nutrient deprivation 
(1, 5, 32). To more fully understand the mechanisms in place in UPEC to cope 
with these challenges, two underappreciated regulatory mechanisms were tested 
for their roles in bacterial stress response and pathogenesis: the regulation of 
gene expression by sRNAs and regulation of translation by tRNA modification.  
 sRNAs modulate many aspects of bacterial gene expression, often in 
association with the RNA chaperone Hfq (35). Previous work has indicated a role 
for Hfq, and likely sRNAs, in UPEC virulence and stress response (22). To 
further define the contribution of sRNAs to UPEC pathogenesis and the observed 
effects of an Hfq deletion, a panel of conserved sRNAs was screened for 
alterations to stress response in vitro as described in Chapter 4. Nearly all tested 
sRNAs exhibited defects in biofilm formation; however, only two knockouts 
exhibited defects in stress resistance, Spot 42 and MicC. A double knockout of 
the two sRNAs showed a synthetic defect, suggesting alternate pathways of 
action. Focus on Spot 42, an sRNA known to affect multiple metabolic pathways, 
revealed altered levels of several metabolic intermediates and a contribution to 
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oxidative stress responses in vitro. Spot 42 also positively affected intracellular 
survival of UPEC in both cell culture and a murine model of infection. 
Extrapolation of these data suggests that UPEC persistence requires fully 
functional metabolic and/or stress response pathways for intracellular survival 
during UTI.  
Much of the mechanistic data surrounding bacterial sRNAs comes from 
analysis of laboratory strains of E. coli, such as MG1655, which, compared to 
wild type strains, fare poorly under stressful challenges and are severely 
attenuated outside of laboratory conditions (6, 36). The study of sRNAs in UPEC 
provides the opportunity to test their roles in host-pathogen interactions and 
robust stress resistance pathways and supplement work in Salmonella and 
enteropathogenic strains of E. coli. In addition to comparing non-pathogens to 
pathogens, the large number of sequenced, annotated E. coli isolates enables 
study of evolutionary aspects of sRNA acquisition and function across strains 
and species. Future analyses highlighting the contributions of sRNA molecules to 
stress response cascades in multiple isolates will likely help to explain the 
process of co-opting genomic features such as sRNAs for use in new genetic 
backgrounds, as has occurred in UPEC.  
 Chapter 5 extended the breadth of UPEC sRNAs by using RNA-Seq to 
identify novel sRNA molecules in UTI89. Putative UPEC sRNA molecules were 
identified both in vitro and in vivo directly from the bladders of infected mice by 
sequencing using an Illumina HiSeq 2000 machine. Novel sRNA molecules were 
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identified from in vitro isolated samples as containing >5 fold increased 
expression compared to neighboring open reading frames (ORFs) as previously 
described (29). The data gained from infected mouse bladders was used to guide 
our selection of candidate sRNAs for further study. Several hundred, candidate 
sRNAs were identified using this approach. Eleven promising candidates, 
exhibiting high relative levels of expression compared to neighboring ORFs, low 
standard deviations, and expression in multiple samples, were chromosomally 
deleted using lambda Red recombination and shown to be modestly defective in 
biofilm formation (10). One particular sRNA, UsrB, appears to slightly repress 
virulence (~4.5 fold) in the mouse UTI model. The mechanism of repression by 
UsrB is unknown at this time, but it is hypothesized that UsrB may regulate 
virulence factor expression in some capacity to prevent overzealous activation of 
virulence cascades, possibly through negative regulation of the PhoR-PhoP two 
component system controlling inorganic phosphate levels, as discussed in 
Chapter 5 (8, 16). In addition to testing regulation of PhoR, much work remains 
surrounding the candidate sRNA molecules. Several additional putative sRNAs, 
including UPEC-specific sRNAs, still remain to be chromosomally deleted. All of 
the candidate sRNAs require validation by complementation, Northern blot 
analysis, and 5’ and 3’ end mapping by RACE to determine the exact size and 
sequence of the sRNAs. Further characterization of their effects on stress 
response and virulence are also forthcoming. Overall, RNA-Seq provided us with 
more support for UPEC as a valid system in which to elucidate and further 
characterize sRNA function, and has opened many avenues of future research.  
	  	   	  
220	  
 In Chapter 6, the global role of tRNA modifications in UPEC stress 
response and virulence was tested. Chromosomal knockouts were generated in 
two enzymes, MiaA and MiaB that modify adenosine-37 in a subset of tRNA 
molecules (7, 27). Knockouts indicated differential control of virulence and stress 
responses by MiaA and MiaB. MiaB appeared to influence only biofilm formation, 
whereas MiaA exhibited defects in nearly all tested aspects of stress response, 
metabolism, and virulence, including production of the α-hemolysin toxin. In 
particular, a knockout of MiaA was defective in survival and colonization of the 
bladder: at 3 days postinoculation, UPEC lacking MiaA showed a 10,000-fold 
decrease in titers relative to the wild type strain. Interestingly, despite a severe 
defect in bladder colonization, MiaA knockouts still formed reservoir populations 
albeit significantly decreased in size. The relative defect in reservoir formation 
was quite small compared to the defect in bladder colonization observed at 3 
days postinfection, suggesting that the intracellular niche provides UPEC with a 
more hospitable habitat for long-term persistence in the urinary tract as 
compared to the bladder lumen.  
In addition to learning more of UPEC biology in the urinary tract through 
studies of tRNA modifications, several interesting mechanisms of regulation by 
tRNA modifications were elucidated in these studies. Specifically, changes in 
MiaA expression through the use of either a gene knockout or overexpression 
constructs resulted in defective stress resistance, suggesting a requirement for 
proper MiaA gene dosage in responding to stressful conditions. MiaA protein 
levels were shown to decrease in response to environmental oxidative stress in 
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the form of methyl viologen. Altered gene dosage of MiaA also influenced various 
aspects of motility, with overexpression completely preventing swarm motility, 
while a MiaA knockout exhibited more robust swarming than wild type. It has 
previously been hypothesized that tRNA modifying enzymes may act as global 
regulators of stress response due to their pleiotropic affects on translation (9). In 
this model, levels of tRNA modification serve to alter the translational landscape 
by providing altered flexibility to protein structures, through changes in 
translational fidelity. The results presented here support this idea, as MiaA was 
shown to regulate multiple stress response pathways, behavioral transitions, and 
virulence, dependent upon levels of MiaA expression. Manipulation of MiaA 
expression levels resulted in pleiotropic effects, suggesting that MiaA acts as a 
global regulator of UPEC stress response, virulence, and behavior.  
The study of two separate enzymes, MiaA and MiaB, required to modify 
the same tRNA residue, provides a noteworthy comparison of the functional 
diversity arising from different tRNA modifications. MiaA affects growth and 
survival of UPEC under nearly all conditions and stresses tested, whereas MiaB 
only contributed to biofilm formation in our assays. It will be interesting to assess 
the contribution of other A-37 modifications on stress resistance and virulence in 
UPEC - e.g., the YfiC enzyme that modifies valine-recognizing tRNAs and 
contributes to K-12 stress resistance (15). In addition to YfiC, many other tRNA 
modification enzymes present in the UPEC genome could be assessed for 
virulence and stress response regulation. Previously published and ongoing gene 
expression profiling and mutant screens may highlight tRNA modifying enzymes 
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that are likely important for infection. Overall, a direct comparison of MiaA and 
MiaB functions in UPEC has revealed that MiaB, but not MiaA, is dispensable for 
many aspects of UPEC stress response, behavior, and virulence. These 
conclusions would be difficult to make using only K-12 E. coli strains that are less 
amenable to use with phenotypic assays that gauge stress resistance and 
virulence beyond what K-12 strains can handle. Thus UPEC serves as a valuable 
system in which to study conserved mechanisms of regulation, such as sRNAs 
and tRNA modifying enzymes, which may be difficult to discern using standard 
attenuated K-12 strains.  
The contents of this thesis cover a wide-range of topics relevant to host-
pathogen interactions. The common theme throughout, however, is the 
maintenance and persistence of UPEC reservoir populations in the urinary tract. 
Initially, attempts were made to eradicate the UPEC reservoirs through use of 
highly cell-permeable antibiotics. On their own, these antibiotics had little effect 
on the reservoirs, but when coupled with a potent exfoliant (chitosan), the 
reservoirs were more readily targeted. In order to understand the maintenance of 
the reservoir, studies were performed on the mechanisms utilized by UPEC to 
regulate virulence traits and to cope with environmental stresses. Results 
presented indicate that both the sRNA repertoire and tRNA modification 
pathways promote UPEC resistance persistence.  
Ultimately, this dissertation asserts that the UPEC reservoir population is 
an impervious, staunch foe. Despite advanced therapies, bacteria persist in the 
urinary tract, in part due to a reservoir population that reinoculates the bladder 
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lumen to trigger subsequent rounds of infection. In the future, novel, more cell-
permeable therapeutics may be developed that can more effectively transit the 
urothelial barrier to eradicate bacteria, or perhaps more potent antibiotics might 
be identified that better eliminate metabolically inactive, quiescent bacteria. A 
new series of drugs targeting metabolically inactive M. tuberculosis promises 
hope that such novel therapeutics could be developed to target UPEC reservoirs 
in the future (14, 31). The adaptation and application of similar treatments 
towards quiescent UPEC populations within the urinary tract will necessitate 
further basic research into UPEC pathogenesis, similar to data presented in 
chapters 4 through 6. In addition to providing a model for treatment of chronic 
UTIs, this thesis established UPEC as a robust system in which to study bacterial 
sRNA molecules and tRNA modifying enzymes. Future studies aimed at defining 
the contributions of additional conserved sRNAs to virulence and stress response 
will help to elucidate both the regulation and evolution of these RNA molecules. 
Likewise, tRNA molecules are a fundamental building block of biology: and 
continued work in UPEC will help further the understanding of these essential 
modifications as global regulators of bacterial behavior. Together, these 
regulatory mechanisms provide UPEC with the tools needed to respond to 
environmental challenges and persist in the urinary tract through formation and 
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Reprint of:  Blango, M.G. and Mulvey, M.A. (2009). Bacterial landlines: contact-
dependent signaling in bacterial populations. Current Opinion in Microbiology 12, 
1-5. Reprinted with permission of Elsevier Limited.  
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UROPATHOGENIC ESCHERICHIA COLI INDUCES           
SERUM AMYLOID A IN MICE FOLLOWING 
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et al. (2012) Uropathogenic Escherichia coli Induces Serum Amyloid A in Mice 
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